

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 15/12, C07K 14/51, 16/22	A1	(11) International Publication Number: WO 00/29579 (43) International Publication Date: 25 May 2000 (25.05.00)
(21) International Application Number: PCT/US99/26909		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 12 November 1999 (12.11.99)		
(30) Priority Data: 09/191,986 13 November 1998 (13.11.98) US		
(71) Applicant: ZYMOGENETICS, INC. [US/US]; 1201 Eastlake Avenue East, Seattle, WA 98102 (US).		
(72) Inventors: LOK, Si; 806 NW 52nd Street, Seattle, WA 98107 (US). PRESNELL, Scott, R.; 2902 N. Puget Sound Avenue, Tacoma, WA 98407 (US).		
(74) Agent: LUNN, Paul, G.; ZymoGenetics, Inc., 1201 Eastlake Avenue East, Seattle, WA 98102 (US).		
(54) Title: MAMMALIAN CHONDROMODULIN-LIKE PROTEIN		<p>Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
(57) Abstract		<p>The present invention relates to polynucleotide and polypeptide molecules for mammalian chondromodulin-like polypeptide.</p>

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

MAMMALIAN CHONDROMODULIN-LIKE PROTEIN

5

BACKGROUND OF THE INVENTION

The chondromodulin-I (Chm-I) is a factor described from bovine cartilage [Hiraki et al. *BBRC*, 175: 971-977 (1991),
10 Hiraki et al. *J. Biol. Chem.* 271: 22657-22662 (1996). Chm-I was first reported as an 18 kilodalton (kD) glycoprotein purified from bovine nasal cartilage. The complete amino acid sequence of the purified protein was reported by Neame et al. *J. Biol. Chem.* 265: 9628-9633 (1990). Later,
15 a cDNA encoding what is believed to be a polymorphic variant of this protein, differing by two amino acid residues, was isolated from a bovine fetal epiphysial cartilage cDNA library by Hiraki et al., *BBRC*, 175:971-977 (1991). A human ortholog to bovine Chm-I was discovered by
20 Hirai et al. European Patent Application Serial No. EP-624645-A. filed May 11, 1994.

Human and bovine Chm-I share a high degree of structural sequence conservation. Bovine Chm-I is produced
25 as a 335 amino acid precursor polypeptide with features common to the class II cell surface proteins. Most notably, the precursor polypeptide has a nonclassical leader sequence that is followed by a hydrophobic putative transmembrane domain (TMD) sequence. Proteolytic cleavage
30 of the precursor polypeptide gives rise to a mature active protein consisting of the carboxyl-terminal 121 amino acid residues. A processing signal (Arg-Glu-Arg-Arg, SEQ ID NO:10) precedes the mature protein sequence.
35 Mature bovine and human Chm-I have two domains. One domain covers the amino-terminal half of the mature

protein. The amino-domain is rather hydrophilic and contains all the potential glycosylation sites and exhibits less sequence conservation than the carboxy-terminal domain. The carboxyl-terminal domain contains a 5 hydrophobic region and eight cysteine residues. This domain is highly conserved in bovine and human Chm-I. The residues are 98% identical in this region. The carboxyl-terminal domain of mature Chm-I has been shown to be highly proteinase resistant and is believed to be tightly 10 folded, Neame et al., *J. Biol. Chem.* 265: 9628-9633 (1990). Expression of a cDNA encoding the Chm-I precursor protein in COS-1 cells produces a processed Chm-I protein in the culture supernatant that appears to be structurally and functionally identical to native matured protein.

15 Bovine *Chm-I* transcripts are found only in cartilaginous tissues. High transcript levels are located in chondrocytes, especially abundant in cells in the proliferating cartilage zones, Hiraki et al., *J. Biol. Chem.*, 272: 32419-32426 (1997). *Chm-I* expression is 20 localized specifically to the avascular zones of cartilage in the developing bone and is not expressed in calcifying cartilage nor in bony or the surrounding soft tissues. Immunohistochemical study indicates *Chm-I* protein co- 25 localizes with its transcript.

Chm-I has a number of bone and cartilage related biological activities. *Chm-I* has been shown to stimulate osteoblast proliferation, Mori et al. *FEBS Lett.*, 406: 30 310-314 (1997). Bovine *Chm-I* is shown to stimulate DNA synthesis of culture growth-plate chondrocytes in the presence of basic fibroblast growth factor (FGF), Hiraki et al., *BBRC*, 175: 971-977 (1991). It appears to function 35 as an autocrine chondrocyte colony-stimulating factor, which synergizes with FGF-2 to stimulate colony formation of growth plate chondrocytes in agarose cultures, Inoue et

al. *BBRC*, 241: 395-400 (1997). Most recently, Chm-I has been identified as an endothelial cell growth inhibitor, Hiraki et al. *FEBS Lett.*, 415:321-324 (1997) and Hiraki et al., *J. Biol. Chem.*, 272: 32419-32426 (1997). This finding 5 suggests that Chm-I has a regulatory role in vascular invasion during endochondral formation and the maintenance of avascularization in cartilage.

There is a need to find additional growth factors which promote the growth of cartilage, muscle, 10 heart and the cells of the mesenchymal tissue lineage in general.

DESCRIPTION OF THE INVENTION

15 The present invention addresses this need by providing novel polypeptides and related compositions and methods. Within one aspect, the present invention provides an isolated polynucleotide encoding a mammalian chondromodulin-like protein termed Zchm1. The human Zchm1 20 polypeptide with signal sequence is comprised of a sequence of amino acids 317 amino acids long with the initial Met as shown in SEQ ID NO:1 and SEQ ID NO:2. Amino acid residues 34-48 of SEQ ID NO:2 may define a transmembrane domain, also defined by SEQ ID NO:3. An 25 alternative transmembrane domain may be defined by amino acid residues 31-50 of SEQ ID NO:2, also defined by SEQ ID NO:4. The lysine residues at positions 213-214 indicate a likely cleavage site between amino acid residue 214, a lysine, and amino acid residue 215, a glycine. This would 30 produce a mature Zchm-1 polypeptide extending from amino acid residue 215, a glycine through amino acid residue 317 of SEQ ID NO:2, also define by SEQ ID NO:5. In an alternative embodiment, the mature sequence extends from amino acid residue 255, a phenylalanine, through amino 35 acid residue 317 of SEQ ID NO:2, also defined by SEQ ID NO:6. Other soluble forms of Zchm-1 include a sequence

extending from amino acid residue 202 through amino acid residue 311 of SEQ ID NO:2 also defined by SEQ ID NO:11, and the sequence extending from amino acid residue 48 through amino acid residue 311 of SEQ ID NO:2 also defined
5 by SEQ ID NO:12.

Within a second aspect of the invention there is provided an expression vector comprising (a) a transcription promoter; (b) a DNA segment encoding Zchm1 polypeptide,
10 and (c) a transcription terminator, wherein the promoter, DNA segment, and terminator are operably linked.

Within a third aspect of the invention there is provided a cultured eukaryotic cell into which has been introduced an
15 expression vector as disclosed above, wherein said cell expresses a protein polypeptide encoded by the DNA segment.

Within a further aspect of the invention there is provided
20 a chimeric polypeptide consisting essentially of a first portion and a second portion joined by a peptide bond. The first portion of the chimeric polypeptide consists essentially of (a) a Zchm1 polypeptide as shown in SEQ ID NO: 2 (b) allelic variants of SEQ ID NO:2; and (c) protein
25 polypeptides that are at least 99% identical to (a) or (b). The second portion of the chimeric polypeptide consists essentially of another polypeptide such as an affinity tag. Within one embodiment the affinity tag is an immunoglobulin F_C polypeptide. The invention also
30 provides expression vectors encoding the chimeric polypeptides and host cells transfected to produce the chimeric polypeptides.

Within an additional aspect of the invention there is
35 provided an antibody that specifically binds to a Zchm1 polypeptide as disclosed above, and also an anti-idiotypic

antibody which neutralizes the antibody to a Zchm1 polypeptide.

An additional embodiment of the present invention relates 5 to a peptide or polypeptide which has the amino acid sequence of an epitope-bearing portion of a Zchm1 polypeptide having an amino acid sequence described above. Peptides or polypeptides having the amino acid sequence of an epitope-bearing portion of a Zchm1 polypeptide of the 10 present invention include portions of such polypeptides with at least nine, preferably at least 15 and more preferably at least 30 to 50 amino acids, although epitope-bearing polypeptides of any length up to and including the entire amino acid sequence of a polypeptide 15 of the present invention described above are also included in the present invention. Examples of such polypeptides are polypeptides comprised of SEQ ID NOS: 2, 5, 6, 11, 12 and 16-22. Also claimed are any of these polypeptides that are fused to another polypeptide or carrier molecule.

20

Prior to setting forth the invention in detail, it may be helpful to the understanding thereof to define the following terms:

25 The term "affinity tag" is used herein to denote a polypeptide segment that can be attached to a second polypeptide to provide for purification or detection of the second polypeptide or provide sites for attachment of the second polypeptide to a substrate. In principal, any 30 peptide or protein for which an antibody or other specific binding agent is available can be used as an affinity tag. Affinity tags include a poly-histidine tract, protein A, Nilsson et al., *EMBO J.* 4:1075 (1985); Nilsson et al., *Methods Enzymol.* 198:3 (1991), glutathione S transferase, 35 Smith and Johnson, *Gene* 67:31 (1988), Glu-Glu affinity tag, Grussenmeyer et al., *Proc. Natl. Acad. Sci. USA*

82:7952-4 (1985), substance P, Flag™ peptide, Hopp et al., *Biotechnology* 6:1204-1210 (1988), streptavidin binding peptide, or other antigenic epitope or binding domain. See, in general, Ford et al., *Protein Expression and*

- 5 *Purification* 2: 95-107 (1991). DNAs encoding affinity tags are available from commercial suppliers (e.g., Pharmacia Biotech, Piscataway, NJ).

The term "allelic variant" is used herein to

- 10 denote any of two or more alternative forms of a gene occupying the same chromosomal locus. Allelic variation arises naturally through mutation, and may result in phenotypic polymorphism within populations. Gene mutations can be silent (no change in the encoded 15 polypeptide) or may encode polypeptides having altered amino acid sequence. The term allelic variant is also used herein to denote a protein encoded by an allelic variant of a gene.

- 20 The terms "amino-terminal" and "carboxyl-terminal" are used herein to denote positions within polypeptides. Where the context allows, these terms are used with reference to a particular sequence or portion of a polypeptide to denote proximity or relative position.

- 25 For example, a certain sequence positioned carboxyl-terminal to a reference sequence within a polypeptide is located proximal to the carboxyl terminus of the reference sequence, but is not necessarily at the carboxyl terminus of the complete polypeptide.

30

- The term "complement/anti-complement pair" denotes non-identical moieties that form a non-covalently associated, stable pair under appropriate conditions. For instance, biotin and avidin (or streptavidin) are 35 prototypical members of a complement/anti-complement pair. Other exemplary complement/anti-complement pairs include

receptor/ligand pairs, antibody/antigen (or hapten or epitope) pairs, sense/antisense polynucleotide pairs, and the like. Where subsequent dissociation of the complement/anti-complement pair is desirable, the 5 complement/anti-complement pair preferably has a binding affinity of <10⁹ M⁻¹.

The term "complements of a polynucleotide molecule" is a polynucleotide molecule having a 10 complementary base sequence and reverse orientation as compared to a reference sequence. For example, the sequence 5' ATGCACGGG 3' is complementary to 5' CCCGTGCAT 3'.

The term "contig" denotes a polynucleotide that 15 has a contiguous stretch of identical or complementary sequence to another polynucleotide. Contiguous sequences are said to "overlap" a given stretch of polynucleotide sequence either in their entirety or along a partial stretch of the polynucleotide. For example, 20 representative contigs to the polynucleotide sequence 5'-ATGGCTTAGCTT-3' are 5'-TAGCTTgagtct-3' and 3'-gtcgacTACCGA-5'.

The term "degenerate nucleotide sequence" 25 denotes a sequence of nucleotides that includes one or more degenerate codons (as compared to a reference polynucleotide molecule that encodes a polypeptide). Degenerate codons contain different triplets of nucleotides, but encode the same amino acid residue (i.e., 30 GAU and GAC triplets each encode Asp).

The term "expression vector" is used to denote a DNA molecule, linear or circular, that comprises a segment encoding a polypeptide of interest operably linked to 35 additional segments that provide for its transcription. Such additional segments include promoter and terminator sequences, and may also include one or more origins of

replication, one or more selectable markers, an enhancer, a polyadenylation signal, etc. Expression vectors are generally derived from plasmid or viral DNA, or may contain elements of both.

5

The term "isolated", when applied to a polynucleotide, denotes that the polynucleotide has been removed from its natural genetic milieu and is thus free of other extraneous or unwanted coding sequences, and is 10 in a form suitable for use within genetically engineered protein production systems. Such isolated molecules are those that are separated from their natural environment and include cDNA and genomic clones. Isolated DNA molecules of the present invention are free of other genes 15 with which they are ordinarily associated, but may include naturally occurring 5' and 3' untranslated regions such as promoters and terminators. The identification of associated regions will be evident to one of ordinary skill in the art (see for example, Dynan and Tijan, *Nature* 20 316:774-78 (1985).

An "isolated" polypeptide or protein is a polypeptide or protein that is found in a condition other than its native environment, such as apart from blood and 25 animal tissue. In a preferred form, the isolated polypeptide is substantially free of other polypeptides, particularly other polypeptides of animal origin. It is preferred to provide the polypeptides in a highly purified form, i.e. greater than 95% pure, more preferably greater 30 than 99% pure. When used in this context, the term "isolated" does not exclude the presence of the same polypeptide in alternative physical forms, such as dimers or alternatively glycosylated or derivatized forms.

35 The term "operably linked", when referring to DNA segments, indicates that the segments are arranged so that they function in concert for their intended purposes,

e.g., transcription initiates in the promoter and proceeds through the coding segment to the terminator.

The term "ortholog" denotes a polypeptide or
5 protein obtained from one species that is the functional counterpart of a polypeptide or protein from a different species. Sequence differences among orthologs are the result of speciation.

10 "Paralogs" are distinct but structurally related proteins made by an organism. Paralogs are believed to arise through gene duplication. For example, α -globin, β -globin, and myoglobin are paralogs of each other.

15 A "polynucleotide" is a single- or double-stranded polymer of deoxyribonucleotide or ribonucleotide bases read from the 5' to the 3' end. Polynucleotides include RNA and DNA, and may be isolated from natural sources, synthesized *in vitro*, or prepared from a
20 combination of natural and synthetic molecules. Sizes of polynucleotides are expressed as base pairs (abbreviated "bp"), nucleotides ("nt"), or kilobases ("kb"). Where the context allows, the latter two terms may describe polynucleotides that are single-stranded or double-
25 stranded. When the term is applied to double-stranded molecules it is used to denote overall length and will be understood to be equivalent to the term "base pairs". It will be recognized by those skilled in the art that the two strands of a double-stranded polynucleotide may differ
30 slightly in length and that the ends thereof may be staggered as a result of enzymatic cleavage; thus all nucleotides within a double-stranded polynucleotide molecule may not be paired. Such unpaired ends will in general not exceed 20 nt in length.

A "polypeptide" is a polymer of amino acid residues joined by peptide bonds, whether produced naturally or synthetically. Polypeptides of less than about 10 amino acid residues are commonly referred to as 5 "peptides".

The term "promoter" is used herein for its art-recognized meaning to denote a portion of a gene containing DNA sequences that provide for the binding of 10 RNA polymerase and initiation of transcription. Promoter sequences are commonly, but not always, found in the 5' non-coding regions of genes.

A "protein" is a macromolecule comprising one or 15 more polypeptide chains. A protein may also comprise non-peptidic components, such as carbohydrate groups. Carbohydrates and other non-peptidic substituents may be added to a protein by the cell in which the protein is produced, and will vary with the type of cell. Proteins 20 are defined herein in terms of their amino acid backbone structures; substituents such as carbohydrate groups are generally not specified, but may be present nonetheless.

The term "receptor" denotes a cell-associated 25 protein that binds to a bioactive molecule (i.e., a ligand) and mediates the effect of the ligand on the cell. Membrane-bound receptors are characterized by a multi-domain structure comprising an extracellular ligand-binding domain and an intracellular effector domain that 30 is typically involved in signal transduction. Binding of ligand to receptor results in a conformational change in the receptor that causes an interaction between the effector domain and other molecule(s) in the cell. This interaction in turn leads to an alteration in the 35 metabolism of the cell. Metabolic events that are linked to receptor-ligand interactions include gene transcription, phosphorylation, dephosphorylation,

increases in cyclic AMP production, mobilization of cellular calcium, mobilization of membrane lipids, cell adhesion, hydrolysis of inositol lipids and hydrolysis of phospholipids. In general, receptors can be membrane bound, cytosolic or nuclear; monomeric (e.g., thyroid stimulating hormone receptor, beta-adrenergic receptor) or multimeric (e.g., PDGF receptor, growth hormone receptor, IL-3 receptor, GM-CSF receptor, G-CSF receptor, erythropoietin receptor and IL-6 receptor).

10

The term "secretory signal sequence" denotes a DNA sequence that encodes a polypeptide (a "secretory peptide") that, as a component of a larger polypeptide, directs the larger polypeptide through a secretory pathway of a cell in which it is synthesized. The larger polypeptide is commonly cleaved to remove the secretory peptide during transit through the secretory pathway.

The term "splice variant" is used herein to denote alternative forms of RNA transcribed from a gene. Splice variation arises naturally through use of alternative splicing sites within a transcribed RNA molecule, or less commonly between separately transcribed RNA molecules, and may result in several mRNAs transcribed from the same gene. Splice variants may encode polypeptides having altered amino acid sequence. The term splice variant is also used herein to denote a protein encoded by a splice variant of an mRNA transcribed from a gene.

30

Molecular weights and lengths of polymers determined by imprecise analytical methods (e.g., gel electrophoresis) will be understood to be approximate values. When such a value is expressed as "about" X or "approximately" X, the stated value of X will be understood to be accurate to $\pm 10\%$.

The present invention addresses this need by providing novel polypeptides and related compositions and methods. Within one aspect, the present invention provides

5 an isolated polynucleotide encoding a mammalian chondromodulin-like protein termed Zchm1. The human Zchm1 polypeptide with signal sequence is comprised of a sequence of amino acids 317 amino acids long with the initial Met as shown in SEQ ID NO:1 and SEQ ID NO:2. Amino

10 acid residues 34-48 of SEQ ID NO:2 may define a transmembrane domain, also defined by SEQ ID NO:3. An alternative transmembrane domain may be defined by amino acid residues 31-50 of SEQ ID NO:2, also defined by SEQ ID NO:4. The lysine residues at positions 213-214 indicate a

15 likely cleavage site between amino acid residue 214, a lysine, and amino acid residue 215, a glycine. This would produce a mature Zchm-1 polypeptide extending from amino acid residue 215, a glycine through amino acid residue 317 of SEQ ID NO:2, also define by SEQ ID NO:5. In an

20 alternative embodiment, the mature sequence extends from amino acid residue 255, a phenylalanine, through amino acid residue 317 of SEQ ID NO:2, also defined by SEQ ID NO:6.

25 The absence of a classical leader sequence and the presence of an amino-terminal hydrophobic sequence, the transmembrane domain, are structural features of the class II cell surface proteins. As such, Zchm-1 may be anchored on the cell membrane via its transmembrane domain and

30 oriented with its carboxyl-terminus outwards. Bovine Chm-I precursor protein is believed to adopt the same configuration on the cell surface, Hiraki *et al.* *BBRC*, 175: 971-977 (1991).

35 Alignment of bovine and human precursor Chm-I with Zchm-1 sequences reveals a major region of similarity residing

within the carboxy-terminal most 63 amino acid residues. This region of Zchm-1 (residues 255-316) of SEQ ID NO:2 corresponds to the carboxyl-terminal domain of the mature and processed form of bovine and human Chm-I and exhibits 5 65% sequence identity. Seven of the eight cysteine positions in this region of Zchm-1 (Cys265, Cys266, Cys269, Cys276, Cys280, Cys300 and Cys306) are identical in bovine and human Chm-I, with the single remaining cysteine residue (Cys292) off set by four residue 10 positions toward the amino-terminus in Chm-I. It is predicted that the high degree of sequence conservation along with the near perfect conservation of cysteine positions would result in residues 255-317 adopting one of two possible disulfide bond patterns deduced for bovine 15 Chm-I, Neame et al., *J. Biol. Chem.*, 265: 9628-9633 (1990).

Amino acid sequence conservation between ZchmI and Chm-I drops off rapidly for sequences preceding Zchm-1 residue 20 255 of SEQ ID NO:2. The analogous region of bovine and human Chm-I corresponds to the N-terminal domain of the mature protein which is also less conserved between human and bovine Chm-I. The decreased sequence conservation in Chm-I suggests that this region of the protein and perhaps 25 that of Zchm-1 may be functionally less important.

The conserved dibasic cleavage site that give rise to mature bovine and human Chm-I is not present in Zchm-1, an alternative dibasic cleavage site may be present at 30 amino acid residues 213-214 of SEQ ID NO:2. Other than this site there are no obvious alternative processing site in Zchm-1 corresponding to the cleavage site of Chm-I. Accordingly, mature Zchm-1 polypeptide may be a membrane bound protein. There are examples of families of growth 35 factors such as tumor necrosis factors, in which family members are either soluble or are membrane dependent on susceptibility to proteolytic processing.

POLYNUCLEOTIDES:

The present invention also provides polynucleotide molecules, including DNA and RNA molecules, 5 that encode the Zchm1 polypeptides disclosed herein. Those skilled in the art will readily recognize that, in view of the degeneracy of the genetic code, considerable sequence variation is possible among these polynucleotide molecules.

10

Polynucleotides, generally a cDNA sequence, of the present invention encode the described polypeptides herein. A cDNA sequence which encodes a polypeptide of the present invention is comprised of a series of codons, 15 each amino acid residue of the polypeptide being encoded by a codon and each codon being comprised of three nucleotides. The amino acid residues are encoded by their respective codons as follows.

20 Alanine (Ala) is encoded by GCA, GCC, GCG or GCT;

Cysteine (Cys) is encoded by TGC or TGT;

Aspartic acid (Asp) is encoded by GAC or GAT;

Glutamic acid (Glu) is encoded by GAA or GAG;

25 Phenylalanine (Phe) is encoded by TTC or TTT;

Glycine (Gly) is encoded by GGA, GGC, GGG or

GGT;

Histidine (His) is encoded by CAC or CAT;

Isoleucine (Ile) is encoded by ATA, ATC or ATT;

30 Lysine (Lys) is encoded by AAA, or AAG;

Leucine (Leu) is encoded by TTA, TTG, CTA, CTC, CTG or CTT;

Methionine (Met) is encoded by ATG;

Asparagine (Asn) is encoded by AAC or AAT;

35 Proline (Pro) is encoded by CCA, CCC, CCG or CCT;

Glutamine (Gln) is encoded by CAA or CAG;

Arginine (Arg) is encoded by AGA, AGG, CGA, CGC, CGG or CGT;

Serine (Ser) is encoded by AGC, AGT, TCA, TCC, TCG or TCT;

5 Threonine (Thr) is encoded by ACA, ACC, ACG or ACT;

Valine (Val) is encoded by GTA, GTC, GTG or GTT;

Tryptophan (Trp) is encoded by TGG; and

Tyrosine (Tyr) is encoded by TAC or TAT.

10

It is to be recognized that according to the present invention, when a polynucleotide is claimed as described herein, it is understood that what is claimed are both the sense strand, the anti-sense strand, and the

15 DNA as double-stranded having both the sense and anti-sense strand annealed together by their respective hydrogen bonds. Also claimed is the messenger RNA (mRNA) which encodes the polypeptides of the present invention, and which mRNA is encoded by the cDNA described herein.

20 Messenger RNA (mRNA) will encode a polypeptide using the same codons as those defined herein, with the exception that each thymine nucleotide (T) is replaced by a uracil nucleotide (U).

25 One of ordinary skill in the art will also appreciate that different species can exhibit "preferential codon usage." In general, see, Grantham, et al., *Nuc. Acids Res.* 8:1893-1912 (1980); Haas, et al.

Curr. Biol. 6:315-324 (1996); Wain-Hobson, et al., *Gene*

30 13:355-364 (1981); Grosjean and Fiers, *Gene* 18:199-209

(1982); Holm, *Nuc. Acids Res.* 14:3075-3087 (1986);

Ikemura, *J. Mol. Biol.* 158:573-597 (1982). As used

herein, the term "preferential codon usage" or

"preferential codons" is a term of art referring to

35 protein translation codons that are most frequently used in cells of a certain species, thus favoring one or a few

representatives of the possible codons encoding each amino acid. For example, the amino acid Threonine (Thr) may be encoded by ACA, ACC, ACG, or ACT, but in mammalian cells ACC is the most commonly used codon; in other species, for 5 example, insect cells, yeast, viruses or bacteria, different Thr codons may be preferential. Preferential codons for a particular species can be introduced into the polynucleotides of the present invention by a variety of methods known in the art. Introduction of preferential 10 codon sequences into recombinant DNA can, for example, enhance production of the protein by making protein translation more efficient within a particular cell type or species. Sequences containing preferential codons can be tested and optimized for expression in various species, 15 and tested for functionality as disclosed herein.

Within preferred embodiments of the invention the isolated polynucleotides will hybridize to similar sized regions of SEQ ID NO:1, or a sequence complementary 20 thereto, under stringent conditions. In general, stringent conditions are selected to be about 5°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength and pH) at 25 which 50% of the target sequence hybridizes to a perfectly matched probe. Typical stringent conditions are those in which the salt concentration is up to about 0.03 M at pH 7 and the temperature is at least about 60°C.

As previously noted, the isolated 30 polynucleotides of the present invention include DNA and RNA. Methods for preparing DNA and RNA are well known in the art. In general, RNA is isolated from a tissue or cell that produces large amounts of Zchm1 RNA. Such 35 tissues and cells are identified by Northern blotting, Thomas, Proc. Natl. Acad. Sci. USA 77:5201 (1980), and

include bone marrow and muscle. Total RNA can be prepared using guanidine HCl extraction followed by isolation by centrifugation in a CsCl gradient, Chirgwin et al., *Biochemistry* 18:52-94 (1979). Poly (A)⁺ RNA is prepared from total RNA using the method of Aviv and Leder, *Proc. Natl. Acad. Sci. USA* 69:1408-1412 (1972). Complementary DNA (cDNA) is prepared from poly(A)⁺ RNA using known methods. In the alternative, genomic DNA can be isolated. Polynucleotides encoding Zchm1 polypeptides are then identified and isolated by, for example, hybridization or PCR.

A full-length clone encoding Zchm1 can be obtained by conventional cloning procedures. Complementary DNA (cDNA) clones are preferred, although for some applications (e.g., expression in transgenic animals) it may be preferable to use a genomic clone, or to modify a cDNA clone to include at least one genomic intron. Methods for preparing cDNA and genomic clones are well known and within the level of ordinary skill in the art, and include the use of the sequence disclosed herein, or parts thereof, for probing or priming a library. Expression libraries can be probed with antibodies to Zchm1, receptor fragments, or other specific binding partners.

The polynucleotides of the present invention can also be synthesized using DNA synthesizers. Currently the method of choice is the phosphoramidite method. If chemically synthesized double stranded DNA is required for an application such as the synthesis of a gene or a gene fragment, then each complementary strand is made separately. The production of short genes (60 to 80 bp) is technically straightforward and can be accomplished by synthesizing the complementary strands and then annealing them. For the production of longer genes (>300 bp),

however, special strategies must be invoked, because the coupling efficiency of each cycle during chemical DNA synthesis is seldom 100%. To overcome this problem, synthetic genes (double-stranded) are assembled in modular form from single-stranded fragments that are from 20 to 100 nucleotides in length. See Glick and Pasternak, *Molecular Biotechnology, Principles & Applications of Recombinant DNA*, (ASM Press, Washington, D.C. 1994); Itakura et al., *Annu. Rev. Biochem.* 53: 323-356 (1984) and Climie et al., *Proc. Natl. Acad. Sci. USA* 87:633-637 (1990).

The present invention further provides counterpart polypeptides and polynucleotides from other species (orthologs). These species include, but are not limited to mammalian, avian, amphibian, reptile, fish, insect and other vertebrate and invertebrate species. Of particular interest are Zchm1 polypeptides from other mammalian species, including murine, porcine, ovine, bovine, canine, feline, equine, and other primate polypeptides. Orthologs of human Zchm1 can be cloned using information and compositions provided by the present invention in combination with conventional cloning techniques. For example, a cDNA can be cloned using mRNA obtained from a tissue or cell type that expresses Zchm1 as disclosed herein. Suitable sources of mRNA can be identified by probing Northern blots with probes designed from the sequences disclosed herein. A library is then prepared from mRNA of a positive tissue or cell line. A Zchm1-encoding cDNA can then be isolated by a variety of methods, such as by probing with a complete or partial human cDNA or with one or more sets of degenerate probes based on the disclosed sequences. A cDNA can also be cloned using the polymerase chain reaction, or PCR (Mullis, U.S. Patent No. 4,683,202), using primers designed from the representative human Zchm1 sequence

disclosed herein. Within an additional method, the cDNA library can be used to transform or transfect host cells, and expression of the cDNA of interest can be detected with an antibody to Zchm1 polypeptide. Similar techniques 5 can also be applied to the isolation of genomic clones.

Those skilled in the art will recognize that the sequence disclosed in SEQ ID NO:1 represents a single allele of human Zchm1 and that allelic variation and 10 alternative splicing are expected to occur. Allelic variants of this sequence can be cloned by probing cDNA or genomic libraries from different individuals according to standard procedures. Allelic variants of the DNA sequence shown in SEQ ID NO:1, including those containing 15 silent mutations and those in which mutations result in amino acid sequence changes, are within the scope of the present invention, as are proteins which are allelic variants of SEQ ID NO:2. cDNAs generated from alternatively spliced mRNAs, which retain the properties 20 of the Zchm1 polypeptide are included within the scope of the present invention, as are polypeptides encoded by such cDNAs and mRNAs. Allelic variants and splice variants of these sequences can be cloned by probing cDNA or genomic libraries from different individuals or tissues according 25 to standard procedures known in the art.

The present invention also provides isolated Zchm1 polypeptides that are substantially homologous to the polypeptides of SEQ ID NO:2 and their orthologs. The 30 term "substantially homologous" is used herein to denote polypeptides having 50%, preferably 60%, more preferably at least 80%, sequence identity to the sequences shown in SEQ ID NO:2 or their orthologs. Such polypeptides will more preferably be at least 90% identical, and most 35 preferably 95% or more identical to SEQ ID NO:2 or its orthologs.) Percent sequence identity is determined by conventional methods. See, for example, Altschul et al.,

Bull. Math. Bio. 48: 603-616 (1986) and Henikoff and Henikoff, Proc. Natl. Acad. Sci. USA 89:10915-10919 (1992). Briefly, two amino acid sequences are aligned to optimize the alignment scores using a gap opening penalty of 10, a gap extension penalty of 1, and the "BLOSUM 62" scoring matrix of Henikoff and Henikoff (*ibid.*) as shown in Table 1 (amino acids are indicated by the standard one-letter codes). The percent identity is then calculated as:

10 Total number of identical matches
 $\frac{\text{length of the longer sequence plus the}}{\text{number of gaps introduced into the longer}} \times 100$
 sequence in order to align the two sequences]

Table 1

	A	R	N	D	C	Q	E	G	H	I	L	K	M	F	P	S	T	W	Y	V
5	A	4																		
	R	-1	5																	
	N	-2	0	6																
	D	-2	-2	1	6															
10	C	0	-3	-3	-3	9														
	Q	-1	1	0	0	-3	5													
	E	-1	0	0	2	-4	2	5												
	G	0	-2	0	-1	-3	-2	-2	6											
	H	-2	0	1	-1	-3	0	0	-2	8										
	I	-1	-3	-3	-3	-1	-3	-3	-4	-3	4									
	L	-1	-2	-3	-4	-1	-2	-3	-4	-3	2	4								
15	K	-1	2	0	-1	-3	1	1	-2	-1	-3	-2	5							
	M	-1	-1	-2	-3	-1	0	-2	-3	-2	1	2	-1	5						
	F	-2	-3	-3	-2	-3	-3	-3	-1	0	0	-3	0	6						
	P	-1	-2	-2	-1	-3	-1	-1	-2	-2	-3	-3	-1	-2	-4	7				
	S	1	-1	1	0	-1	0	0	0	-1	-2	-2	0	-1	-2	-1	4			
	T	0	-1	0	-1	-1	-1	-2	-2	-1	-1	-1	-2	-1	-1	-2	-1	1	5	
20	W	-3	-3	-4	-4	-2	-2	-3	-2	-2	-3	-2	-3	-1	1	-4	-3	-2	11	
	Y	-2	-2	-3	-2	-1	-2	-3	2	-1	-2	-1	-2	-1	3	-3	-2	-2	7	
	V	0	-3	-3	-3	-1	-2	-2	-3	-3	3	1	-2	1	-1	-2	-2	0	-3	-1

Sequence identity of polynucleotide molecules is determined by similar methods using a ratio as disclosed above.

5 Variant Zchm1 polypeptides or substantially homologous Zchm1 polypeptides are characterized as having one or more amino acid substitutions, deletions or additions. These changes are preferably of a minor nature, that is conservative amino acid substitutions (see
10 Table 2) and other substitutions that do not significantly affect the folding or activity of the polypeptide; small deletions, typically of one to about 30 amino acids; and small amino- or carboxyl-terminal extensions, such as an amino-terminal methionine residue, a small linker peptide
15 of up to about 20-25 residues, or an affinity tag. The present invention thus includes polypeptides of from 20 to 30 amino acid residues that comprise a sequence that is at least 90%, preferably at least 95%, and more preferably 99% or more identical to the corresponding region of SEQ
20 ID NO:4. Polypeptides comprising affinity tags can further comprise a proteolytic cleavage site between the Zchm1 polypeptide and the affinity tag. Preferred such sites include thrombin cleavage sites and factor Xa cleavage sites.

Table 2Conservative amino acid substitutions

5

	Basic:	arginine lysine histidine
10	Acidic:	glutamic acid aspartic acid
	Polar:	glutamine asparagine
	Hydrophobic:	leucine isoleucine
15		valine
	Aromatic:	phenylalanine tryptophan tyrosine
20	Small:	glycine alanine serine threonine methionine

25

The present invention further provides a variety of other polypeptide fusions [and related multimeric proteins comprising one or more polypeptide fusions]. For example, a Zchm1 polypeptide can be prepared as a fusion

to a dimerizing protein as disclosed in U.S. Patents Nos. 5,155,027 and 5,567,584. Preferred dimerizing proteins in this regard include immunoglobulin constant region

domains. Immunoglobulin-Zchm1 polypeptide fusions can be expressed in genetically engineered cells [to produce a variety of multimeric Zchm1 analogs]. Auxiliary domains can be fused to Zchm1 polypeptides to target them to specific cells, tissues, or macromolecules (e.g.,

30 35 collagen). For example, a Zchm1 polypeptide or protein

could be targeted to a predetermined cell type by fusing a Zchm1 polypeptide to a ligand that specifically binds to a receptor on the surface of the target cell. In this way, polypeptides and proteins can be targeted for therapeutic or diagnostic purposes. A Zchm1 polypeptide can be fused to two or more moieties, such as an affinity tag for purification and a targeting domain. Polypeptide fusions can also comprise one or more cleavage sites, particularly between domains. See, Tuan et al., *Connective Tissue Research* 34:1-9 (1996).

The proteins of the present invention can also comprise non-naturally occurring amino acid residues. Non-naturally occurring amino acids include, without limitation, *trans*-3-methylproline, 2,4-methanoproline, *cis*-4-hydroxyproline, *trans*-4-hydroxyproline, *N*-methylglycine, allo-threonine, methylthreonine, hydroxyethylcysteine, hydroxyethylhomocysteine, nitroglutamine, homoglutamine, pipecolic acid, thiazolidine carboxylic acid, dehydroproline, 3- and 4-methylproline, 3,3-dimethylproline, *tert*-leucine, norvaline, 2-azaphenylalanine, 3-azaphenylalanine, 4-azaphenylalanine, and 4-fluorophenylalanine. Several methods are known in the art for incorporating non-naturally occurring amino acid residues into proteins. For example, an *in vitro* system can be employed wherein nonsense mutations are suppressed using chemically aminoacylated suppressor tRNAs.

Methods for synthesizing amino acids and aminoacylating tRNA are known in the art. Transcription and translation of plasmids containing nonsense mutations is carried out in a cell-free system comprising an *E. coli* S30 extract and commercially available enzymes and other reagents. Proteins are purified by chromatography. See,

for example, Robertson et al., *J. Am. Chem. Soc.* 113:2722 (1991); Ellman et al., *Methods Enzymol.* 202:301 (1991); Chung et al., *Science* 259:806-809 (1993); and Chung et al., *Proc. Natl. Acad. Sci. USA* 90:10145-1019 (1993). In

5 a second method, translation is carried out in *Xenopus* oocytes by microinjection of mutated mRNA and chemically aminoacylated suppressor tRNAs, Turcatti et al., *J. Biol. Chem.* 271:19991-19998 (1996). Within a third method, *E. coli* cells are cultured in the absence of a natural amino acid that is to be replaced (e.g., phenylalanine) and in the presence of the desired non-naturally occurring amino acid(s) (e.g., 2-azaphenylalanine, 3-azaphenylalanine, 4-azaphenylalanine, or 4-fluorophenylalanine). The non-naturally occurring amino acid is incorporated into the protein in place of its natural counterpart. See, Koide et al., *Biochem.* 33:7470-7476 (1994). Naturally occurring amino acid residues can be converted to non-naturally occurring species by *in vitro* chemical modification.

Chemical modification can be combined with site-directed mutagenesis to further expand the range of substitutions, Wynn and Richards, *Protein Sci.* 2:395-403 (1993).

A limited number of non-conservative amino acids, amino acids that are not encoded by the genetic code, non-naturally occurring amino acids, and unnatural amino acids may be substituted for Zchm1 amino acid residues.

Essential amino acids in the polypeptides of the present invention can be identified according to procedures known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis, Cunningham and Wells, *Science* 244: 1081-1085 (1989); Bass et al., *Proc. Natl. Acad. Sci. USA* 88:4498-502 (1991). In the

latter technique, single alanine mutations are introduced at every residue in the molecule, and the resultant mutant molecules are tested for biological activity as disclosed below to identify amino acid residues that are critical to
5 the activity of the molecule. See also, Hilton et al., *J. Biol. Chem.* 271:4699-708, 1996. Sites of ligand-receptor interaction can also be determined by physical analysis of structure, as determined by such techniques as nuclear magnetic resonance, crystallography, electron diffraction
10 or photoaffinity labeling, in conjunction with mutation of putative contact site amino acids. See, for example, de Vos et al., *Science* 255:306-312 (1992); Smith et al., *J. Mol. Biol.* 224:899-904 (1992); Wlodaver et al., *FEBS Lett.* 309:59-64 (1992).

15

Multiple amino acid substitutions can be made and tested using known methods of mutagenesis and screening, such as those disclosed by Reidhaar-Olson and Sauer, *Science* 241:53-57 (1988) or Bowie and Sauer, *Proc. Natl. Acad. Sci. USA* 86:2152-2156 (1989). Briefly, these authors disclose methods for simultaneously randomizing two or more positions in a polypeptide, selecting for functional polypeptide, and then sequencing the mutagenized polypeptides to determine the spectrum of
25 allowable substitutions at each position. Other methods that can be used include phage display, e.g., Lowman et al., *Biochem.* 30:10832-10837 (1991); Ladner et al., U.S. Patent No. 5,223,409; Huse, WIPO Publication WO 92/06204) and region-directed mutagenesis, Derbyshire et al., *Gene*
30 46:145 (1986); Ner et al., *DNA* 7:127 (1988).

Variants of the disclosed Zchm1 DNA and polypeptide sequences can be generated through DNA shuffling as disclosed by Stemmer, *Nature* 370:389-391,

(1994), Stemmer, *Proc. Natl. Acad. Sci. USA* 91:10747-10751 (1994) and WIPO Publication WO 97/20078. Briefly, variant DNAs are generated by *in vitro* homologous recombination by random fragmentation of a parent DNA followed by 5 reassembly using PCR, resulting in randomly introduced point mutations. This technique can be modified by using a family of parent DNAs, such as allelic variants or DNAs from different species, to introduce additional variability into the process. Selection or screening for 10 the desired activity, followed by additional iterations of mutagenesis and assay provides for rapid "evolution" of sequences by selecting for desirable mutations while simultaneously selecting against detrimental changes.

15 Mutagenesis methods as disclosed herein can be combined with high-throughput, automated screening methods to detect activity of cloned, mutagenized polypeptides in host cells. Mutagenized DNA molecules that encode active polypeptides can be recovered from the host cells and 20 rapidly sequenced using modern equipment. These methods allow the rapid determination of the importance of individual amino acid residues in a polypeptide of interest, and can be applied to polypeptides of unknown structure.

25 Using the methods discussed herein, one of ordinary skill in the art can identify and/or prepare a variety of polypeptide fragments or variants of SEQ ID NO:2 or that retain the properties of the wild-type Zchm1 30 protein.

For any Zchm1 polypeptide, including variants and fusion proteins, one of ordinary skill in the art can readily generate a fully degenerate polynucleotide 35 sequence encoding that variant using the information set forth in Tables 1 and 2 above.

PROTEIN PRODUCTION

The Zchm1 polypeptides of the present invention, including full-length polypeptides, biologically active fragments, and fusion polypeptides, can be produced in genetically engineered host cells according to conventional techniques. Suitable host cells are those cell types that can be transformed or transfected with exogenous DNA and grown in culture, and include bacteria, 10 fungal cells, and cultured higher eukaryotic cells. Eukaryotic cells, particularly cultured cells of multicellular organisms, are preferred. Techniques for manipulating cloned DNA molecules and introducing exogenous DNA into a variety of host cells are disclosed 15 by Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd ed., (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989), and Ausubel et al., eds., *Current Protocols in Molecular Biology* (John Wiley and Sons, Inc., NY, 1987).

20

In general, a DNA sequence encoding a Zchm1 polypeptide is operably linked to other genetic elements required for its expression, generally including a transcription promoter and terminator, within an 25 expression vector. The vector will also commonly contain one or more selectable markers and one or more origins of replication, although those skilled in the art will recognize that within certain systems selectable markers may be provided on separate vectors, and replication of 30 the exogenous DNA may be provided by integration into the host cell genome. Selection of promoters, terminators, selectable markers, vectors and other elements is a matter of routine design within the level of ordinary skill in the art. Many such elements are described in the 35 literature and are available through commercial suppliers.

To direct a Zchm1 polypeptide into the secretory pathway of a host cell, a secretory signal sequence (also known as a leader sequence, prepro sequence or pre sequence) is provided in the expression vector. The 5 secretory signal sequence may be that of Zchm1, or may be derived from another secreted protein (e.g., t-PA) or synthesized de novo. The secretory signal sequence is operably linked to the Zchm1 DNA sequence, i.e., the two sequences are joined in the correct reading frame and 10 positioned to direct the newly synthesized polypeptide into the secretory pathway of the host cell. Secretory signal sequences are commonly positioned 5' to the DNA sequence encoding the polypeptide of interest, although certain secretory signal sequences may be positioned 15 elsewhere in the DNA sequence of interest (see, e.g., Welch et al., U.S. Patent No. 5,037,743; Holland et al., U.S. Patent No. 5,143,830).

Alternatively, the secretory signal sequence 20 contained in the polypeptides of the present invention is used to direct other polypeptides into the secretory pathway. The present invention provides for such fusion polypeptides. The secretory signal sequence contained in the fusion polypeptides of the present invention is 25 preferably fused amino-terminally to an additional peptide to direct the additional peptide into the secretory pathway. Such constructs have numerous applications known in the art. For example, these novel secretory signal sequence fusion constructs can direct the secretion of an 30 active component of a normally non-secreted protein, such as a receptor. Such fusions may be used *in vivo* or *in vitro* to direct peptides through the secretory pathway.

Cultured mammalian cells are suitable hosts 35 within the present invention. Methods for introducing exogenous DNA into mammalian host cells include calcium

phosphate-mediated transfection, Wigler et al., *Cell* 14:725 (1978); Corsaro and Pearson, *Somatic Cell Genetics* 7:603 (1981); Graham and Van der Eb, *Virology* 52:456 (1973), electroporation, Neumann et al., *EMBO J.* 1:841-845 (1982), DEAE-dextran mediated transfection (Ausubel et al., *ibid.*, and liposome-mediated transfection, Hawley-Nelson et al., *Focus* 15:73 (1993); Ciccarone et al., *Focus* 15:80 (1993), and viral vectors, Miller and Rosman, *BioTechniques* 7:980(1989); Wang and Finer, *Nature Med.* 10 2:714 (1996). The production of recombinant polypeptides in cultured mammalian cells is disclosed, for example, by Levinson et al., U.S. Patent No. 4,713,339; Hagen et al., U.S. Patent No. 4,784,950; Palmiter et al., U.S. Patent No. 4,579,821; and Ringold, U.S. Patent No. 4,656,134.

15 Suitable cultured mammalian cells include the COS-1 (ATCC No. CRL 1650), COS-7 (ATCC No. CRL 1651), BHK (ATCC No. CRL 1632), BHK 570 (ATCC No. CRL 10314), 293 (ATCC No. CRL 1573; Graham et al., *J. Gen. Virol.* 36:59 (1977) and Chinese hamster ovary (e.g. CHO-K1; ATCC No. CCL 61) cell lines. Additional suitable cell lines are known in the art and available from public depositories such as the American Type Culture Collection, Rockville, Maryland. In general, strong transcription promoters are preferred, such as promoters from SV-40 or cytomegalovirus. See, e.g., U.S. Patent No. 4,956,288. Other suitable promoters include those from metallothionein genes (U.S. Patent Nos. 4,579,821 and 4,601,978) and the adenovirus major late promoter.

30 Drug selection is generally used to select for cultured mammalian cells into which foreign DNA has been inserted. Such cells are commonly referred to as "transfectants". Cells that have been cultured in the presence of the selective agent and are able to pass the

gene of interest to their progeny are referred to as "stable transfecants." A preferred selectable marker is a gene encoding resistance to the antibiotic neomycin. Selection is carried out in the presence of a neomycin-type drug, such as G-418 or the like. Selection systems can also be used to increase the expression level of the gene of interest, a process referred to as "amplification." Amplification is carried out by culturing transfecants in the presence of a low level of the selective agent and then increasing the amount of selective agent to select for cells that produce high levels of the products of the introduced genes. A preferred amplifiable selectable marker is dihydrofolate reductase, which confers resistance to methotrexate.

Other drug resistance genes (e.g. hygromycin resistance, multi-drug resistance, puromycin acetyltransferase) can also be used. Alternative markers that introduce an altered phenotype, such as green fluorescent protein, or cell surface proteins such as CD4, CD8, Class I MHC, placental alkaline phosphatase may be used to sort transfected cells from untransfected cells by such means as FACS sorting or magnetic bead separation technology.

Other higher eukaryotic cells can also be used as hosts, including plant cells, insect cells and avian cells. The use of *Agrobacterium rhizogenes* as a vector for expressing genes in plant cells has been reviewed by Sinkar et al., *J. Biosci. (Bangalore)* 11:47 (1987). Transformation of insect cells and production of foreign polypeptides therein is disclosed by Guarino et al., U.S. Patent No. 5,162,222 and WIPO publication WO 94/06463. Insect cells can be infected with recombinant baculovirus, commonly derived from *Autographa californica* nuclear polyhedrosis virus (AcNPV). DNA encoding the Zchm1 polypeptide is inserted into the baculoviral genome in place of the AcNPV polyhedrin gene coding sequence by one

of two methods. The first is the traditional method of homologous DNA recombination between wild-type AcNPV and a transfer vector containing the Zchm1 flanked by AcNPV sequences. Suitable insect cells, e.g. SF9 cells, are
5 infected with wild-type AcNPV and transfected with a transfer vector comprising a Zchm1 polynucleotide operably linked to an AcNPV polyhedrin gene promoter, terminator, and flanking sequences. See, King, L.A. and Possee, R.D., *The Baculovirus Expression System: A Laboratory Guide*,
10 (Chapman & Hall, London); O'Reilly, D.R. et al., *Baculovirus Expression Vectors: A Laboratory Manual* (Oxford University Press, New York, New York, 1994); and, Richardson, C. D., Ed., *Baculovirus Expression Protocols. Methods in Molecular Biology*, (Humana Press, Totowa, NJ
15 1995). Natural recombination within an insect cell will result in a recombinant baculovirus which contains Zchm1 driven by the polyhedrin promoter. Recombinant viral stocks are made by methods commonly used in the art.

20 The second method of making recombinant baculovirus utilizes a transposon-based system described by Luckow, V.A, et al., *J Virol* 67:4566 (1993). This system is sold in the Bac-to-Bac kit (Life Technologies, Rockville, MD). This system utilizes a transfer vector,
25 pFastBac1™ (Life Technologies) containing a Tn7 transposon to move the DNA encoding the Zchm1 polypeptide into a baculovirus genome maintained in *E. coli* as a large plasmid called a "bacmid." The pFastBac1™ transfer vector utilizes the AcNPV polyhedrin promoter to drive the
30 expression of the gene of interest, in this case Zchm1. However, pFastBac1™ can be modified to a considerable degree. The polyhedrin promoter can be removed and substituted with the baculovirus basic protein promoter (also known as Pcor, p6.9 or MP promoter) which is
35 expressed earlier in the baculovirus infection, and has

been shown to be advantageous for expressing secreted proteins. See, Hill-Perkins, M.S. and Possee, R.D., *J Gen Virol* 71:971 (1990); Bonning, B.C. et al., *J Gen Virol* 75:1551 (1994); and, Chazenbalk, G.D., and Rapoport, B., *J Biol Chem* 270:1543 (1995). In such transfer vector constructs, a short or long version of the basic protein promoter can be used. Moreover, transfer vectors can be constructed which replace the native Zchm1 secretory signal sequences with secretory signal sequences derived from insect proteins. For example, a secretory signal sequence from Ecdysteroid Glucosyltransferase (EGT), honey bee Melittin (Invitrogen, Carlsbad, CA), or baculovirus gp67 (PharMingen, San Diego, CA) can be used in constructs to replace the native Zchm1 secretory signal sequence. In addition, transfer vectors can include an in-frame fusion with DNA encoding an epitope tag at the C- or N-terminus of the expressed Zchm1 polypeptide, for example, a Glu-Glu epitope tag, Grussenmeyer, T. et al., *Proc Natl Acad Sci.* 82:7952 (1985). Using a technique known in the art, a transfer vector containing Zchm1 is transformed into *E. coli*, and screened for bacmids which contain an interrupted lacZ gene indicative of recombinant baculovirus. The bacmid DNA containing the recombinant baculovirus genome is isolated, using common techniques, and used to transfect *Spodoptera frugiperda* cells, e.g. Sf9 cells. Recombinant virus that expresses Zchm1 is subsequently produced. Recombinant viral stocks are made by methods commonly used the art.

The recombinant virus is used to infect host cells, typically a cell line derived from the fall army worm, *Spodoptera frugiperda*. See, in general, Glick and Pasternak, *Molecular Biotechnology: Principles and Applications of Recombinant DNA* (ASM Press, Washington, D.C., 1994). Another suitable cell line is the High

FiveO™ cell line (Invitrogen) derived from *Trichoplusia ni* (U.S. Patent #5,300,435). Commercially available serum-free media are used to grow and maintain the cells.

Suitable media are Sf900 II™ (Life Technologies) or ESF

5 921™ (Expression Systems) for the Sf9 cells; and Ex-cell0405™ (JRH Biosciences, Lenexa, KS) or Express FiveO™ (Life Technologies) for the *T. ni* cells. The cells are grown up from an inoculation density of approximately 2-5 x 10⁵ cells to a density of 1-2 x 10⁶ cells at which time a
10 recombinant viral stock is added at a multiplicity of infection (MOI) of 0.1 to 10, more typically near 3. The recombinant virus-infected cells typically produce the recombinant Zchm1 polypeptide at 12-72 hours post-infection and secrete it with varying efficiency into the
15 medium. The culture is usually harvested 48 hours post-infection. Centrifugation is used to separate the cells from the medium (supernatant). The supernatant containing the Zchm1 polypeptide is filtered through micropore filters, usually 0.45 µm pore size. Procedures used are
20 generally described in available laboratory manuals (King, L. A. and Possee, R.D., *ibid.*; O'Reilly, D.R. et al., *ibid.*; Richardson, C. D., *ibid.*). Subsequent purification of the Zchm1 polypeptide from the supernatant can be achieved using methods described herein.

25

Fungal cells, including yeast cells, can also be used within the present invention. Yeast species of particular interest in this regard include *Saccharomyces cerevisiae*, *Pichia pastoris*, and *Pichia methanolica*.

30 Methods for transforming *S. cerevisiae* cells with exogenous DNA and producing recombinant polypeptides therefrom are disclosed by, for example, Kawasaki, U.S. Patent No. 4,599,311; Kawasaki et al., U.S. Patent No. 4,931,373; Brake, U.S. Patent No. 4,870,008; Welch et al.,

U.S. Patent No. 5,037,743; and Murray et al., U.S. Patent No. 4,845,075. Transformed cells are selected by phenotype determined by the selectable marker, commonly drug resistance or the ability to grow in the absence of a particular nutrient (e.g., leucine). A preferred vector system for use in *Saccharomyces cerevisiae* is the *POT1* vector system disclosed by Kawasaki et al. (U.S. Patent No. 4,931,373), which allows transformed cells to be selected by growth in glucose-containing media. Suitable promoters and terminators for use in yeast include those from glycolytic enzyme genes (see, e.g., Kawasaki, U.S. Patent No. 4,599,311; Kingsman et al., U.S. Patent No. 4,615,974; and Bitter, U.S. Patent No. 4,977,092) and alcohol dehydrogenase genes. See also U.S. Patents Nos. 4,990,446; 5,063,154; 5,139,936 and 4,661,454.

Transformation systems for other yeasts, including *Hansenula polymorpha*, *Schizosaccharomyces pombe*, *Kluyveromyces lactis*, *Kluyveromyces fragilis*, *Ustilago maydis*, *Pichia pastoris*, *Pichia methanolica*, *Pichia guillermondii* and *Candida maltosa* are known in the art. See, for example, Gleeson et al., *J. Gen. Microbiol.* 132:3459 (1986) and Cregg, U.S. Patent No. 4,882,279.

Aspergillus cells may be utilized according to the methods of McKnight et al., U.S. Patent No. 4,935,349. Methods for transforming *Acremonium chrysogenum* are disclosed by Sumino et al., U.S. Patent No. 5,162,228. Methods for transforming *Neurospora* are disclosed by Lambowitz, U.S. Patent No. 4,486,533.

The use of *Pichia methanolica* as host for the production of recombinant proteins is disclosed in WIPO Publications WO 97/17450, WO 97/17451, WO 98/02536, and WO 98/02565. DNA molecules for use in transforming *P.*

methanolica will commonly be prepared as double-stranded, circular plasmids, which are preferably linearized prior to transformation. For polypeptide production in *P. methanolica*, it is preferred that the promoter and

5 terminator in the plasmid be that of a *P. methanolica* gene, such as a *P. methanolica* alcohol utilization gene (AUG1 or AUG2). Other useful promoters include those of the dihydroxyacetone synthase (DHAS), formate dehydrogenase (FMD), and catalase (CAT) genes. To

10 facilitate integration of the DNA into the host chromosome, it is preferred to have the entire expression segment of the plasmid flanked at both ends by host DNA sequences. A preferred selectable marker for use in *Pichia methanolica* is a *P. methanolica* ADE2 gene, which

15 encodes phosphoribosyl-5-aminoimidazole carboxylase (AIRC; EC 4.1.1.21), which allows ade2 host cells to grow in the absence of adenine. For large-scale, industrial processes where it is desirable to minimize the use of methanol, it is preferred to use host cells in which both methanol

20 utilization genes (AUG1 and AUG2) are deleted. For production of secreted proteins, host cells deficient in vacuolar protease genes (*PEP4* and *PRB1*) are preferred.

Electroporation is used to facilitate the introduction of a plasmid containing DNA encoding a polypeptide of

25 interest into *P. methanolica* cells. It is preferred to transform *P. methanolica* cells by electroporation using an exponentially decaying, pulsed electric field having a field strength of from 2.5 to 4.5 kV/cm, preferably about 3.75 kV/cm, and a time constant (t) of from 1 to 40

30 milliseconds, most preferably about 20 milliseconds.

Prokaryotic host cells, including strains of the bacteria *Escherichia coli*, *Bacillus* and other genera are also useful host cells within the present invention.

Techniques for transforming these hosts and expressing foreign DNA sequences cloned therein are well known in the art, see, e.g., Sambrook et al., *ibid.*). When expressing a Zchm1 polypeptide in bacteria such as *E. coli*, the

5 polypeptide may be retained in the cytoplasm, typically as insoluble granules, or may be directed to the periplasmic space by a bacterial secretion sequence. In the former case, the cells are lysed, and the granules are recovered and denatured using, for example, guanidine isothiocyanate

10 or urea. The denatured polypeptide can then be refolded and dimerized by diluting the denaturant, such as by dialysis against a solution of urea and a combination of reduced and oxidized glutathione, followed by dialysis against a buffered saline solution. In the latter case,

15 the polypeptide can be recovered from the periplasmic space in a soluble and functional form by disrupting the cells (by, for example, sonication or osmotic shock) to release the contents of the periplasmic space and recovering the protein, thereby obviating the need for

20 denaturation and refolding.

Transformed or transfected host cells are cultured according to conventional procedures in a culture medium containing nutrients and other components required

25 for the growth of the chosen host cells. A variety of suitable media, including defined media and complex media, are known in the art and generally include a carbon source, a nitrogen source, essential amino acids, vitamins and minerals. Media may also contain such components as

30 growth factors or serum, as required. The growth medium will generally select for cells containing the exogenously added DNA by, for example, drug selection or deficiency in an essential nutrient which is complemented by the selectable marker carried on the expression vector or co-

35 transfected into the host cell. *P. methanolica* cells are cultured in a medium comprising adequate sources of

carbon, nitrogen and trace nutrients at a temperature of about 25°C to 35°C. Liquid cultures are provided with sufficient aeration by conventional means, such as shaking of small flasks or sparging of fermentors. A preferred culture medium for *P. methanolica* is YEPD (2% D-glucose, 5 2% Bacto™ Peptone (Difco Laboratories, Detroit, MI), 1% Bacto™ yeast extract (Difco Laboratories), 0.004% adenine and 0.006% L-leucine).

10 Protein Isolation

It is preferred to purify the polypeptides of the present invention to ≥80% purity, more preferably to ≥90% purity, even more preferably ≥95% purity, and 15 particularly preferred is a pharmaceutically pure state, that is greater than 99.9% pure with respect to contaminating macromolecules, particularly other proteins and nucleic acids, and free of infectious and pyrogenic agents. Preferably, a purified polypeptide is 20 substantially free of other polypeptides, particularly other polypeptides of animal origin.

Expressed recombinant Zchm1 polypeptides (or chimeric Zchm1 polypeptides) can be purified using 25 fractionation and/or conventional purification methods and media. Ammonium sulfate precipitation and acid or chaotropic extraction may be used for fractionation of samples. Exemplary purification steps may include hydroxyapatite, size exclusion, FPLC and reverse-phase 30 high performance liquid chromatography. Suitable chromatographic media include derivatized dextrans, agarose, cellulose, polyacrylamide, specialty silicas, and the like. PEI, DEAE, QAE and Q derivatives are preferred. Exemplary chromatographic media include those media 35 derivatized with phenyl, butyl, or octyl groups, such as Phenyl-Sepharose FF (Pharmacia), Toyopearl butyl 650 (Toso

Haas, Montgomeryville, PA), Octyl-Sepharose (Pharmacia) and the like; or polyacrylic resins, such as Amberchrom CG 71 (Toso Haas) and the like. Suitable solid supports include glass beads, silica-based resins, cellulosic
5 resins, agarose beads, cross-linked agarose beads, polystyrene beads, cross-linked polyacrylamide resins and the like that are insoluble under the conditions in which they are to be used. These supports may be modified with reactive groups that allow attachment of proteins by amino
10 groups, carboxyl groups, sulfhydryl groups, hydroxyl groups and/or carbohydrate moieties. Examples of coupling chemistries include cyanogen bromide activation, N-hydroxysuccinimide activation, epoxide activation, sulfhydryl activation, hydrazide activation, and carboxyl
15 and amino derivatives for carbodiimide coupling chemistries. These and other solid media are well known and widely used in the art, and are available from commercial suppliers. Methods for binding receptor polypeptides to support media are well known in the art.
20 Selection of a particular method is a matter of routine design and is determined in part by the properties of the chosen support. See, for example, *Affinity Chromatography: Principles & Methods* (Pharmacia LKB Biotechnology, Uppsala, Sweden, 1988).

25

The polypeptides of the present invention can be isolated by exploitation of their properties. For example, immobilized metal ion adsorption (IMAC) chromatography can be used to purify histidine-rich
30 proteins, including those comprising polyhistidine tags. Briefly, a gel is first charged with divalent metal ions to form a chelate, Sulkowski, *Trends in Biochem.* 3:1 (1985). Histidine-rich proteins will be adsorbed to this matrix with differing affinities, depending upon the metal
35 ion used, and will be eluted by competitive elution, lowering the pH, or use of strong chelating agents. Other

methods of purification include purification of glycosylated proteins by lectin affinity chromatography and ion exchange chromatography. *Methods in Enzymol.*, Vol. 182, "Guide to Protein Purification", M. Deutscher, 5 (ed.), page 529-539 (Acad. Press, San Diego, 1990). Within additional embodiments of the invention, a fusion of the polypeptide of interest and an affinity tag (e.g., maltose-binding protein, an immunoglobulin domain) may be constructed to facilitate purification.

10

Moreover, using methods described in the art, polypeptide fusions, or hybrid Zchml proteins, are constructed using regions or domains of the inventive Zchml, Sambrook et al., *ibid.*, Altschul et al., *ibid.*, 15 Picard, *Cur. Opin. Biology*, 5:511 (1994). These methods allow the determination of the biological importance of larger domains or regions in a polypeptide of interest. Such hybrids may alter reaction kinetics, binding, constrict or expand the substrate specificity, or alter 20 tissue and cellular localization of a polypeptide, and can be applied to polypeptides of unknown structure.

Fusion proteins can be prepared by methods known to those skilled in the art by preparing each component of 25 the fusion protein and chemically conjugating them. Alternatively, a polynucleotide encoding both components of the fusion protein in the proper reading frame can be generated using known techniques and expressed by the methods described herein. For example, part or all of a 30 domain(s) conferring a biological function may be swapped between Zchml of the present invention with the functionally equivalent domain(s) from another family member. Such domains include, but are not limited to, the secretory signal sequence, conserved, and significant 35 domains or regions in this family. Such fusion proteins would be expected to have a biological functional profile

that is the same or similar to polypeptides of the present invention or other known family proteins, depending on the fusion constructed. Moreover, such fusion proteins may exhibit other properties as disclosed herein.

5

Zchm1 polypeptides or fragments thereof may also be prepared through chemical synthesis. Zchm1 polypeptides may be monomers or multimers; glycosylated or non-glycosylated; pegylated or non-pegylated; and may or may 10 not include an initial methionine amino acid residue.

Chemical Synthesis of Polypeptides

Polypeptides, especially polypeptides of the present invention can also be synthesized by exclusive 15 solid phase synthesis, partial solid phase methods, fragment condensation or classical solution synthesis. The polypeptides are preferably prepared by solid phase peptide synthesis, for example as described by Merrifield, *J. Am. Chem. Soc.* 85:2149 (1963).

20

ASSAYS

The activity of molecules of the present invention can be measured using a variety of assays. Zchm1 can be measured *in vitro* using cultured cells or *in vivo* 25 by administering molecules of the claimed invention to the appropriate animal model. For instance, Zchm1 transfected (or co-transfected) expression host cells may be embedded in an alginate environment and injected (implanted) into recipient animals. Alginate-poly-L-lysine 30 microencapsulation, permselective membrane encapsulation and diffusion chambers have been described as a means to entrap transfected mammalian cells or primary mammalian cells. These types of non-immunogenic "encapsulations" or microenvironments permit the transfer of nutrients into 35 the microenvironment, and also permit the diffusion of proteins and other macromolecules secreted or released by

the captured cells across the environmental barrier to the recipient animal. Most importantly, the capsules or microenvironments mask and shield the foreign, embedded cells from the recipient animal's immune response. Such 5 microenvironments can extend the life of the injected cells from a few hours or days (naked cells) to several weeks (embedded cells).

An alternative *in vivo* approach for assaying 10 proteins of the present invention involves viral delivery systems. Exemplary viruses for this purpose include adenovirus, herpesvirus, vaccinia virus and adeno-associated virus (AAV). Adenovirus, a double-stranded DNA virus, is currently the best studied gene transfer vector 15 for delivery of heterologous nucleic acid (for a review, see T.C. Becker et al., *Meth. Cell Biol.* 43:161 (1994); and J.T. Douglas and D.T. Curiel, *Science & Medicine* 4:44 (1997). The adenovirus system offers several advantages: adenovirus can (i) accommodate relatively large DNA 20 inserts; (ii) be grown to high-titer; (iii) infect a broad range of mammalian cell types; and (iv) be used with a large number of available vectors containing different promoters. Also, because adenoviruses are stable in the bloodstream, they can be administered by intravenous 25 injection.

By deleting portions of the adenovirus genome, larger inserts (up to 7 kb) of heterologous DNA can be accommodated. These inserts can be incorporated into the 30 viral DNA by direct ligation or by homologous recombination with a co-transfected plasmid. In an exemplary system, the essential E1 gene has been deleted from the viral vector, and the virus will not replicate unless the E1 gene is provided by the host cell (the human 35 293 cell line is exemplary). When intravenously administered to intact animals, adenovirus primarily

targets the liver. If the adenoviral delivery system has an E1 gene deletion, the virus cannot replicate in the host cells. However, the host's tissue (e.g., liver) will express and process (and, if a secretory signal sequence 5 is present, secrete) the heterologous protein. Secreted proteins will enter the circulation in the highly vascularized liver, and effects on the infected animal can be determined.

10 The adenovirus system can also be used for protein production *in vitro*. By culturing adenovirus-infected non-293 cells under conditions where the cells are not rapidly dividing, the cells can produce proteins for extended periods of time. For instance, BHK cells are 15 grown to confluence in cell factories, then exposed to the adenoviral vector encoding the secreted protein of interest. The cells are then grown under serum-free conditions, which allows infected cells to survive for several weeks without significant cell division.

20 Alternatively, adenovirus vector infected 293S cells can be grown in suspension culture at relatively high cell density to produce significant amounts of protein (see Garnier et al., *Cytotechnol.* 15:145 (1994). With either protocol, an expressed, secreted heterologous protein can 25 be repeatedly isolated from the cell culture supernatant. Within the infected 293S cell production protocol, non-secreted proteins may also be effectively obtained.

Agonists and Antagonists

30 In view of the tissue distribution observed for Zchm1, agonists (including the natural ligand/ substrate/ cofactor/ etc.) and antagonists have enormous potential in both *in vitro* and *in vivo* applications. For example, Zchm1 35 and agonist compounds are useful as components of defined cell culture media, and may be used alone or in

combination with other cytokines and hormones to replace serum that is commonly used in cell culture.

Antagonists

5 Antagonists are also useful as research reagents for characterizing sites of ligand-receptor interaction. Also as a treatment for prostate cancer. Inhibitors of Zchm1 activity (Zchm1 antagonists) include anti-Zchm1 antibodies and soluble Zchm1 receptors, as well as other 10 peptidic and non-peptidic agents (including ribozymes). Zchm1 can also be used to identify inhibitors (antagonists) of its activity. Test compounds are added to the assays disclosed herein to identify compounds that inhibit the activity of Zchm1. In addition to those 15 assays disclosed herein, samples can be tested for inhibition of Zchm1 activity within a variety of assays designed to measure receptor binding or the stimulation/inhibition of Zchm1-dependent cellular responses. For example, Zchm1-responsive cell lines can 20 be transfected with a reporter gene construct that is responsive to a Zchm1-stimulated cellular pathway. Reporter gene constructs of this type are known in the art, and will generally comprise a Zchm1-DNA response element operably linked to a gene encoding a protein which 25 can be assayed, such as luciferase. DNA response elements can include, but are not limited to, cyclic AMP response elements (CRE), hormone response elements (HRE) insulin response element (IRE), Nasrin et al., *Proc. Natl. Acad. Sci. USA* 87:5273 (1990) and serum response elements (SRE) 30 (Shaw et al. *Cell* 56: 563 (1989). Cyclic AMP response elements are reviewed in Roestler et al., *J. Biol. Chem.* 263 (19):9063 (1988) and Habener, *Molec. Endocrinol.* 4 (8):1087 (1990). Hormone response elements are reviewed in Beato, *Cell* 56:335 (1989). Candidate compounds, 35 solutions, mixtures or extracts are tested for the ability to inhibit the activity of Zchm1 on the target cells as

evidenced by a decrease in Zchm1 stimulation of reporter gene expression. Assays of this type will detect compounds that directly block Zchm1 binding to cell-surface receptors, as well as compounds that block processes in the cellular pathway subsequent to receptor-ligand binding. In the alternative, compounds or other samples can be tested for direct blocking of Zchm1 binding to receptor using Zchm1 tagged with a detectable label (e.g., ¹²⁵I, biotin, horseradish peroxidase, FITC, and the like). Within assays of this type, the ability of a test sample to inhibit the binding of labeled Zchm1 to the receptor is indicative of inhibitory activity, which can be confirmed through secondary assays. Receptors used within binding assays may be cellular receptors or isolated, immobilized receptors.

A Zchm1 polypeptide can be expressed as a fusion with an immunoglobulin heavy chain constant region, typically an F_C fragment, which contains two constant region domains and lacks the variable region. Methods for preparing such fusions are disclosed in U.S. Patents Nos. 5,155,027 and 5,567,584. Such fusions are typically secreted as multimeric molecules wherein the Fc portions are disulfide bonded to each other and two non-Ig polypeptides are arrayed in closed proximity to each other. Fusions of this type can be used to affinity purify the ligand. For use in assays, the chimeras are bound to a support via the F_C region and used in an ELISA format.

A Zchm1 ligand-binding polypeptide can also be used for purification of ligand. The polypeptide is immobilized on a solid support, such as beads of agarose, cross-linked agarose, glass, cellulosic resins, silica-based resins, polystyrene, cross-linked polyacrylamide, or like materials that are stable under the conditions of

use. Methods for linking polypeptides to solid supports are known in the art, and include amine chemistry, cyanogen bromide activation, N-hydroxysuccinimide activation, epoxide activation, sulfhydryl activation, and 5 hydrazide activation. The resulting medium will generally be configured in the form of a column, and fluids containing ligand are passed through the column one or more times to allow ligand to bind to the receptor polypeptide. The ligand is then eluted using changes in 10 salt concentration, chaotropic agents (guanidine HCl), or pH to disrupt ligand-receptor binding.

An assay system that uses a ligand-binding receptor (or an antibody, one member of a complement/ 15 anti-complement pair) or a binding fragment thereof, and a commercially available biosensor instrument (BIAcore, Pharmacia Biosensor, Piscataway, NJ) may be advantageously employed. Such receptor, antibody, member of a complement/anti-complement pair or fragment is immobilized 20 onto the surface of a receptor chip. Use of this instrument is disclosed by Karlsson, *J. Immunol. Methods* 145:229 (1991) and Cunningham and Wells, *J. Mol. Biol.* 234:554 (1993). A receptor, antibody, member or fragment 25 is covalently attached, using amine or sulfhydryl chemistry, to dextran fibers that are attached to gold film within the flow cell. A test sample is passed through the cell. If a ligand, epitope, or opposite member of the complement/anti-complement pair is present 30 in the sample, it will bind to the immobilized receptor, antibody or member, respectively, causing a change in the refractive index of the medium, which is detected as a change in surface plasmon resonance of the gold film. This system allows the determination of on- and off-rates, 35 from which binding affinity can be calculated, and assessment of stoichiometry of binding. Ligand-binding receptor polypeptides can also be used within other assay

systems known in the art. Such systems include Scatchard analysis for determination of binding affinity, Scatchard, *Ann. NY Acad. Sci.* 51: 660 (1949) and calorimetric assays, Cunningham et al., *Science* 253:545 (1991); Cunningham et 5 al., *Science* 245:821 (1991).

Zchm1 polypeptides can also be used to prepare antibodies that specifically bind to Zchm1 epitopes, peptides or polypeptides. The Zchm1 polypeptide or a 10 fragment thereof serves as an antigen (immunogen) to inoculate an animal and elicit an immune response. Suitable antigens would be the Zchm1 polypeptides encoded by SEQ ID NOS:2-24. Antibodies generated from this immune response can be isolated and purified as described herein. 15 Methods for preparing and isolating polyclonal and monoclonal antibodies are well known in the art. See, for example, *Current Protocols in Immunology*, Cooligan, et al. (eds.), National Institutes of Health, (John Wiley and Sons, Inc., 1995); Sambrook et al., *Molecular Cloning: A 20 Laboratory Manual, Second Edition* (Cold Spring Harbor, NY, 1989); and Hurrell, J. G. R., Ed., *Monoclonal Hybridoma Antibodies: Techniques and Applications* (CRC Press, Inc., Boca Raton, FL, 1982).

25 As would be evident to one of ordinary skill in the art, polyclonal antibodies can be generated from inoculating a variety of warm-blooded animals such as horses, cows, goats, sheep, dogs, chickens, rabbits, mice, and rats with a Zchm1 polypeptide or a fragment thereof. 30 The immunogenicity of a Zchm1 polypeptide may be increased through the use of an adjuvant, such as alum (aluminum hydroxide) or Freund's complete or incomplete adjuvant. Polypeptides useful for immunization also include fusion polypeptides, such as fusions of Zchm1 or a portion 35 thereof with an immunoglobulin polypeptide or with maltose

binding protein. The polypeptide immunogen may be a full-length molecule or a portion thereof. If the polypeptide portion is "hapten-like", such portion may be advantageously joined or linked to a macromolecular 5 carrier (such as keyhole limpet hemocyanin (KLH), bovine serum albumin (BSA) or tetanus toxoid) for immunization.

As used herein, the term "antibodies" includes polyclonal antibodies, affinity-purified polyclonal 10 antibodies, monoclonal antibodies, and antigen-binding fragments, such as $F(ab')_2$ and Fab proteolytic fragments. Genetically engineered intact antibodies or fragments, 15 such as chimeric antibodies, Fv fragments, single chain antibodies and the like, as well as synthetic antigen-binding peptides and polypeptides, are also included. Non-human antibodies may be humanized by grafting non-human CDRs onto human framework and constant regions, or by incorporating the entire non-human variable domains 20 (optionally "cloaking" them with a human-like surface by replacement of exposed residues, wherein the result is a "veeneered" antibody). In some instances, humanized antibodies may retain non-human residues within the human variable region framework domains to enhance proper binding characteristics. Through humanizing antibodies, 25 biological half-life may be increased, and the potential for adverse immune reactions upon administration to humans is reduced.

Alternative techniques for generating or 30 selecting antibodies useful herein include *in vitro* exposure of lymphocytes to Zchm1 protein or peptide, and selection of antibody display libraries in phage or similar vectors (for instance, through use of immobilized or labeled Zchm1 protein or peptide). Genes encoding 35 polypeptides having potential Zchm1 polypeptide binding domains can be obtained by screening random peptide libraries displayed on phage (phage display) or on

bacteria, such as *E. coli*. Nucleotide sequences encoding the polypeptides can be obtained in a number of ways, such as through random mutagenesis and random polynucleotide synthesis. These random peptide display libraries can be 5 used to screen for peptides which interact with a known target which can be a protein or polypeptide, such as a ligand or receptor, a biological or synthetic macromolecule, or organic or inorganic substances.

Techniques for creating and screening such random peptide 10 display libraries are known in the art (Ladner et al., US Patent NO. 5,223,409; Ladner et al., US Patent NO. 4,946,778; Ladner et al., US Patent NO. 5,403,484 and Ladner et al., US Patent NO. 5,571,698) and random peptide display libraries and kits for screening such libraries 15 are available commercially, for instance from Clontech (Palo Alto, CA), Invitrogen Inc. (San Diego, CA), New England Biolabs, Inc. (Beverly, MA) and Pharmacia LKB Biotechnology Inc. (Piscataway, NJ). Random peptide display libraries can be screened using the Zchm1 sequences disclosed herein to identify proteins which bind 20 to Zchm1. These "binding proteins" which interact with Zchm1 polypeptides can be used for tagging cells; for isolating homolog polypeptides by affinity purification; they can be directly or indirectly conjugated to drugs, 25 toxins, radionuclides and the like. These binding proteins can also be used in analytical methods such as for screening expression libraries and neutralizing activity. The binding proteins can also be used for diagnostic assays for determining circulating levels of 30 polypeptides; for detecting or quantitating soluble polypeptides as marker of underlying pathology or disease. These binding proteins can also act as Zchm1 "antagonists" to block Zchm1 binding and signal transduction *in vitro* and *in vivo*. These anti-Zchm1 binding proteins would be 35 useful for inhibiting the effects of Zchm1.

Antibodies are determined to be specifically binding if: (1) they exhibit a threshold level of binding activity, and/or 2) they do not significantly cross-react with related polypeptide molecules. First, antibodies herein specifically bind if they bind to a Zchm1 polypeptide, peptide or epitope with a binding affinity (K_a) of 10^6 M^{-1} or greater, preferably 10^7 M^{-1} or greater, more preferably 10^8 M^{-1} or greater, and most preferably 10^9 M^{-1} or greater. The binding affinity of an antibody can be readily determined by one of ordinary skill in the art, for example, by Scatchard analysis. Second, antibodies are determined to specifically bind if they do not significantly cross-react with related polypeptides.

Antibodies do not significantly cross-react with related polypeptide molecules, for example, if they detect Zchm1 but not known related polypeptides using a standard Western blot analysis (Ausubel et al., *ibid.*). Examples of known related polypeptides are orthologs, proteins from the same species that are members of a protein family (e.g. IL-16), Zchm1 polypeptides, and non-human Zchm1. Moreover, antibodies may be "screened against" known related polypeptides to isolate a population that specifically binds to the inventive polypeptides. For example, antibodies raised to Zchm1 are adsorbed to related polypeptides adhered to insoluble matrix; antibodies specific to Zchm1 will flow through the matrix under the proper buffer conditions. Such screening allows isolation of polyclonal and monoclonal antibodies non-crossreactive to closely related polypeptides, *Antibodies: A Laboratory Manual*, Harlow and Lane (eds.) (Cold Spring Harbor Laboratory Press, 1988); *Current Protocols in Immunology*, Cooligan, et al. (eds.), National Institutes of Health (John Wiley and Sons, Inc., 1995). Screening and isolation of specific antibodies is well known in the

art. See, *Fundamental Immunology*, Paul (eds.) (Raven Press, 1993); Getzoff et al., *Adv. in Immunol.* 43: 1-98 (1988); *Monoclonal Antibodies: Principles and Practice*, Goding, J.W. (eds.), (Academic Press Ltd., 1996); Benjamin 5 et al., *Ann. Rev. Immunol.* 2: 67-101 (1984).

A variety of assays known to those skilled in the art can be utilized to detect antibodies which specifically bind to Zchm1 proteins or peptides.

10 Exemplary assays are described in detail in *Antibodies: A Laboratory Manual*, Harlow and Lane (Eds.) (Cold Spring Harbor Laboratory Press, 1988). Representative examples of such assays include: concurrent immunoelectrophoresis, radioimmunoassay, radioimmuno-precipitation, enzyme-linked 15 immunosorbent assay (ELISA), dot blot or Western blot assay, inhibition or competition assay, and sandwich assay. In addition, antibodies can be screened for binding to wild-type versus mutant Zchm1 protein or polypeptide.

20

Antibodies to Zchm1 may be used for tagging cells that express Zchm1; for isolating Zchm1 by affinity purification; for diagnostic assays for determining circulating levels of Zchm1 polypeptides; for detecting or 25 quantitating soluble Zchm1 as marker of underlying pathology or disease; in analytical methods employing FACS; for screening expression libraries; for generating anti-idiotypic antibodies; and as neutralizing antibodies or as antagonists to block Zchm1 *in vitro* and *in vivo*.

30 Suitable direct tags or labels include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent markers, chemiluminescent markers, magnetic particles and the like; indirect tags or labels may feature use of biotin-avidin or other complement/anti-complement pairs as 35 intermediates. Antibodies herein may also be directly or indirectly conjugated to drugs, toxins, radionuclides and

the like, and these conjugates used for *in vivo* diagnostic or therapeutic applications. Moreover, antibodies to Zchm1 or fragments thereof may be used *in vitro* to detect denatured Zchm1 or fragments thereof in assays, for 5 example, Western Blots or other assays known in the art.

BIOACTIVE CONJUGATES:

Antibodies or polypeptides herein can also be directly or indirectly conjugated to drugs, toxins, 10 radionuclides and the like, and these conjugates used for *in vivo* diagnostic or therapeutic applications. For instance, polypeptides or antibodies of the present invention can be used to identify or treat tissues or organs that express a corresponding anti-complementary 15 molecule (receptor or antigen, respectively, for instance). More specifically, Zchm1 polypeptides or anti-Zchm1 antibodies, or bioactive fragments or portions thereof, can be coupled to detectable or cytotoxic molecules and delivered to a mammal having cells, tissues 20 or organs that express the anti-complementary molecule.

Suitable detectable molecules may be directly or indirectly attached to the polypeptide or antibody, and include radionuclides, enzymes, substrates, cofactors, 25 inhibitors, fluorescent markers, chemiluminescent markers, magnetic particles and the like. Suitable cytotoxic molecules may be directly or indirectly attached to the polypeptide or antibody, and include bacterial or plant toxins (for instance, diphtheria toxin, *Pseudomonas* 30 exotoxin, ricin, abrin and the like), as well as therapeutic radionuclides, such as iodine-131, rhenium-188 or yttrium-90 (either directly attached to the polypeptide or antibody, or indirectly attached through means of a chelating moiety, for instance). Polypeptides or 35 antibodies may also be conjugated to cytotoxic drugs, such as adriamycin. For indirect attachment of a detectable or

cytotoxic molecule, the detectable or cytotoxic molecule can be conjugated with a member of a complementary/anticomplementary pair, where the other member is bound to the polypeptide or antibody portion. For these purposes, 5 biotin/streptavidin is an exemplary complementary/anticomplementary pair.

In another embodiment, polypeptide-toxin fusion proteins or antibody-toxin fusion proteins can be used for 10 targeted cell or tissue inhibition or ablation (for instance, to treat cancer cells or tissues).

Alternatively, if the polypeptide has multiple functional domains (i.e., an activation domain or a ligand binding domain, plus a targeting domain), a fusion protein 15 including only the targeting domain may be suitable for directing a detectable molecule, a cytotoxic molecule or a complementary molecule to a cell or tissue type of interest. In instances where the domain only fusion protein includes a complementary molecule, the anti- 20 complementary molecule can be conjugated to a detectable or cytotoxic molecule. Such domain-complementary molecule fusion proteins thus represent a generic targeting vehicle for cell/tissue-specific delivery of generic anti-complementary-detectable/ cytotoxic molecule conjugates.

25 In another embodiment, Zchm1-cytokine fusion proteins or antibody-cytokine fusion proteins can be used for enhancing *in vivo* killing of target tissues (for example, blood and bone marrow cancers), if the Zchm1 30 polypeptide or anti-Zchm1 antibody targets the hyperproliferative blood or bone marrow cell. See, generally, Hornick et al., *Blood* 89:4437 (1997). They described fusion proteins enable targeting of a cytokine to a desired site of action, thereby providing an elevated 35 local concentration of cytokine. Suitable Zchm1 polypeptides or anti-Zchm1 antibodies target an

undesirable cell or tissue (i.e., a tumor or a leukemia), and the fused cytokine mediated improved target cell lysis by effector cells. Suitable cytokines for this purpose include interleukin 2 and granulocyte-macrophage colony-stimulating factor (GM-CSF), for instance.

In yet another embodiment, if the Zchm1 polypeptide or anti-Zchm1 antibody targets vascular cells or tissues, such polypeptide or antibody may be conjugated with a radionuclide, and particularly with a beta-emitting radionuclide, to reduce restenosis. Such therapeutic approach poses less danger to clinicians who administer the radioactive therapy. For instance, iridium-192 impregnated ribbons placed into stented vessels of patients until the required radiation dose was delivered showed decreased tissue growth in the vessel and greater luminal diameter than the control group, which received placebo ribbons. Further, revascularisation and stent thrombosis were significantly lower in the treatment group. Similar results are predicted with targeting of a bioactive conjugate containing a radionuclide, as described herein.

The bioactive polypeptide or antibody conjugates described herein can be delivered intravenously, intraarterially or intraductally, or may be introduced locally at the intended site of action.

USES OF POLYNUCLEOTIDE/POLYPEPTIDE:

The polypeptides of the present invention can be used as a growth or differentiation regulator for cells, especially those of the mesenchymal, myogenic, chondrogenic and endothelial cells. Preparations of the Zchm-1 can be placed in areas in need of bone or cartilage repair. Zchm-1 can also be administered to muscles or endothelial cells which are in need of repair. Instead of

the polypeptide the *Zchm1* gene can be administered as described below.

GENE THERAPY:

5 Polynucleotides encoding *Zchm1* polypeptides are useful within gene therapy applications where it is desired to increase or inhibit *Zchm1* activity. If a mammal has a mutated or absent *Zchm1* gene, the *Zchm1* gene can be introduced into the cells of the mammal. In one
10 embodiment, a gene encoding a *Zchm1* polypeptide is introduced *in vivo* in a viral vector. Such vectors include an attenuated or defective DNA virus, such as, but not limited to, herpes simplex virus (HSV), papillomavirus, Epstein Barr virus (EBV), adenovirus,
15 adeno-associated virus (AAV), and the like. Defective viruses, which entirely or almost entirely lack viral genes, are preferred. A defective virus is not infective after introduction into a cell. Use of defective viral vectors allows for administration to cells in a specific,
20 localized area, without concern that the vector can infect other cells. Examples of particular vectors include, but are not limited to, a defective herpes simplex virus 1 (HSV1) vector, Kaplitt et al., *Molec. Cell. Neurosci.* 2:320 (1991); an attenuated adenovirus vector, such as the
25 vector described by Stratford-Perricaudet et al., *J. Clin. Invest.* 90:626 (1992); and a defective adeno-associated virus vector, Samulski et al., *J. Virol.* 61:3096 (1987); Samulski et al., *J. Virol.* 63:3822 (1989).

30 In another embodiment, a *Zchm1* gene can be introduced in a retroviral vector, e.g., as described in Anderson et al., U.S. Patent No. 5,399,346; Mann et al. *Cell* 33:153, 1983; Temin et al., U.S. Patent No. 4,650,764; Temin et al., U.S. Patent No. 4,980,289;

Markowitz et al., *J. Virol.* 62:1120 (1988); Temin et al., U.S. Patent No. 5,124,263; International Patent Publication No. WO 95/07358, published March 16, 1995 by Dougherty et al.; and Kuo et al., *Blood* 82:845 (1993).

5 Alternatively, the vector can be introduced by lipofection *in vivo* using liposomes. Synthetic cationic lipids can be used to prepare liposomes for *in vivo* transfection of a gene encoding a marker, Felgner et al., *Proc. Natl. Acad. Sci. USA* 84:7413 (1987); Mackey et al., *Proc. Natl. Acad. Sci. USA* 85:8027 (1988). The use of lipofection to introduce exogenous genes into specific organs *in vivo* has certain practical advantages. Molecular targeting of liposomes to specific cells represents one area of benefit. More particularly, directing transfection to 10 particular cells represents one area of benefit. For instance, directing transfection to particular cell types would be particularly advantageous in a tissue with cellular heterogeneity, such as the pancreas, liver, kidney, and brain. Lipids may be chemically coupled to 15 other molecules for the purpose of targeting. Targeted peptides (e.g., hormones or neurotransmitters), proteins such as antibodies, or non-peptide molecules can be coupled to liposomes chemically.

25 It is possible to remove the target cells from the body; to introduce the vector as a naked DNA plasmid; and then to re-implant the transformed cells into the body. Naked DNA vectors for gene therapy can be introduced into the desired host cells by methods known in 30 the art, e.g., transfection, electroporation, microinjection, transduction, cell fusion, DEAE dextran, calcium phosphate precipitation, use of a gene gun or use of a DNA vector transporter. See, e.g., Wu et al., *J.*

Biol. Chem. 267:963 (1992); Wu et al., *J. Biol. Chem.* 263:14621-4, 1988.

Antisense methodology can be used to inhibit
5 Zchm1 gene transcription, such as to inhibit cell
proliferation in vivo. Polynucleotides that are
complementary to a segment of a Zchm1-encoding
polynucleotide (e.g., a polynucleotide as set forth in SEQ
ID NO:1) are designed to bind to Zchm1-encoding mRNA and
10 to inhibit translation of such mRNA. Such antisense
polynucleotides are used to inhibit expression of Zchm1
polypeptide-encoding genes in cell culture or in a
subject.

15 The present invention also provides reagents
which will find use in diagnostic applications. For
example, the Zchm1 gene, a probe comprising Zchm1 DNA or
RNA or a subsequence thereof can be used to determine if
the Zchm1 gene is present on chromosome 11p15.4 or if a
20 mutation has occurred. Detectable chromosomal aberrations
at the Zchm1 gene locus include, but are not limited to,
aneuploidy, gene copy number changes, insertions,
deletions, restriction site changes and rearrangements.
Such aberrations can be detected using polynucleotides of
25 the present invention by employing molecular genetic
techniques, such as restriction fragment length
polymorphism (RFLP) analysis, short tandem repeat (STR)
analysis employing PCR techniques, and other genetic
linkage analysis techniques known in the art (Sambrook et
30 al., *ibid.*; Ausubel et. al., *ibid.*; Marian, *Chest* 108:255
(1995).

Transgenic mice, engineered to express the Zchm1
gene, and mice that exhibit a complete absence of Zchm1
35 gene function, referred to as "knockout mice", Snouwaert
et al., *Science* 257:1083 (1992), may also be generated,

Lowell et al., *Nature* 366:740-42 (1993). These mice may be employed to study the Zchm1 gene and the protein encoded thereby in an in vivo system.

5 CHROMOSOMAL LOCALIZATION:

Radiation hybrid mapping is a somatic cell genetic technique developed for constructing high-resolution, contiguous maps of mammalian chromosomes (Cox et al., *Science* 250:245 (1990)). Partial or full knowledge 10 of a gene's sequence allows one to design PCR primers suitable for use with chromosomal radiation hybrid mapping panels. Radiation hybrid mapping panels are commercially available which cover the entire human genome, such as the Stanford G3 RH Panel and the GeneBridge 4 RH Panel 15 (Research Genetics, Inc., Huntsville, AL). These panels enable rapid, PCR-based chromosomal localizations and ordering of genes, sequence-tagged sites (STSs), and other nonpolymorphic and polymorphic markers within a region of interest. This includes establishing directly 20 proportional physical distances between newly discovered genes of interest and previously mapped markers. The precise knowledge of a gene's position can be useful for a number of purposes, including: 1) determining if a sequence is part of an existing contig and obtaining 25 additional surrounding genetic sequences in various forms, such as YACs, BACs or cDNA clones; 2) providing a possible candidate gene for an inheritable disease which shows linkage to the same chromosomal region; and 3) cross-referencing model organisms, such as mouse, which 30 may aid in determining what function a particular gene might have. ZChm-1 was mapped to chromosome 11p15.4 region.

Sequence tagged sites (STSs) can also be used 35 independently for chromosomal localization. An STS is a DNA sequence that is unique in the human genome and can be

used as a reference point for a particular chromosome or region of a chromosome. An STS is defined by a pair of oligonucleotide primers that are used in a polymerase chain reaction to specifically detect this site in the presence of all other genomic sequences. Since STSs are based solely on DNA sequence they can be completely described within an electronic database, for example, Database of Sequence Tagged Sites (dbSTS), GenBank, (National Center for Biological Information, National Institutes of Health, Bethesda, MD <http://www.ncbi.nlm.nih.gov>), and can be searched with a gene sequence of interest for the mapping data contained within these short genomic landmark STS sequences.

For pharmaceutical use, the proteins of the present invention are formulated for parenteral, particularly intravenous or subcutaneous, delivery according to conventional methods. Intravenous administration will be by bolus injection or infusion over a typical period of one to several hours. In general, pharmaceutical formulations will include a Zchml protein in combination with a pharmaceutically acceptable vehicle, such as saline, buffered saline, 5% dextrose in water or the like. Formulations may further include one or more excipients, preservatives, solubilizers, buffering agents, albumin to prevent protein loss on vial surfaces, etc. Methods of formulation are well known in the art and are disclosed, for example, in Remington: *The Science and Practice of Pharmacy*, Gennaro, ed., (Mack Publishing Co., Easton, PA, 19th ed., 1995). Therapeutic doses will generally be in the range of 0.1 to 100 µg/kg of patient weight per day, preferably 0.5-20 mg/kg per day, with the exact dose determined by the clinician according to accepted standards, taking into account the nature and severity of the condition to be treated, patient traits, etc. Determination of dose is within the level of

ordinary skill in the art. The proteins may be administered for acute treatment, over one week or less, often over a period of one to three days or may be used in chronic treatment, over several months or years. In 5 particular these preparations can be used to promote bone or cartilage repair.

10

RESEARCH TOOL UTILITY

The polynucleotides provided by the present invention can be used by the research community for various purposes. The polynucleotides can be used to 15 express recombinant protein for analysis, characterization or therapeutic; as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or disease states); as 20 molecular weight markers on Southern gels; as chromosome markers (when labeled) to map related gene positions; to compare with endogenous DNA sequences in patients to identify potential genetic disorders; as probes to hybridize and thus discover novel, related DNA sequences; 25 as a source of information to derive PCR primers for genetic fingerprinting; as a probe to "subtract-out" known sequences in the process of discovering other novel polynucleotides; to raise anti-protein antibodies using DNA immunization techniques; and as an antigen to raise 30 anti-DNA antibodies or elicit another immune response. Where the polynucleotide encodes a protein which binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the polynucleotide can also be used in interaction trap assays 35 [such as, for example, that described in Gyuris et al. Cell 75:791-803 (1993)] to identify polynucleotides

encoding the other protein with which binding occurs or to identify inhibitors of the binding interaction.

The proteins provided by the present invention
5 can similarly be used to raise antibodies or to elicit another immune response: as a reagent (including the labeled reagent) in assays designed to quantitatively determine levels of the protein (or its receptor) in biological fluids; as markers for tissues using labeled
10 antibodies; and to isolate correlative receptors or ligands. Where the protein binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the protein can be used to identify the other protein with which binding occurs or to identify
15 inhibitors of the binding interaction. Proteins involved in these binding interactions can also be used to screen for peptide or small molecule inhibitors or agonists of the binding interaction.

20 Any or all of these "research tool" utilities are capable of being developed into reagent grade or kit format for commercialization as "research products".

Cytokine and Cell Proliferation/Differentiation Activity

25

A protein of the present invention may exhibit cytokine-cell proliferation (either inducing or inhibiting) or cell differentiation (either inducing or inhibiting) activity or may induce production of other
30 cytokines in certain cell populations. Many protein factors discovered to date, including all known cytokines, have exhibited activity in one or more factor dependent cell proliferation assays, and hence the assays serve as a convenient confirmation of cytokine activity. The
35 activity of a protein of the present invention is evidenced by any one of a number of routine factor dependent cell proliferation assays for cell lines

including without limitation, 32D, DA2, DA1G, T10, B9, B9/11, BaF3, MC9/G, M+(preB M+), 2E8, RB5, DA1,123, T1165, HT2, CTLL2, TF-1, Mo7e and CMK.

5 The activity of a protein of the invention may, among other means, be measured by assays for T-cell or thymocyte proliferation, assays for cytokine production or proliferation of spleen cells, lymph node cells or thymocytes, assays for proliferation and differentiation
10 of hematopoietic and lymphopoietic cells, and assays for T-cell clone responses to antigens which will identify, among others, proteins that affect antigen-presenting cells (APC)/T-cell interactions as well as direct T-cell effects by measuring proliferation and cytokine
15 production. Other immunological assays include assays for T-cell dependent immunoglobulin responses and isotype switching (which will identify, among others, proteins that modulate T-cell dependent antibody responses and that affect Th1/Th2 profiles); mixed lymphocyte reaction
20 (MLR) assays (which will identify proteins that generate predominantly Th1 and CTL responses); dendritic cell-dependent assays (which will identify, among others, proteins expressed a by dendritic cells that activate naive T-cells); assays for lymphocyte survival/apoptosis
25 (which will identify proteins that prevent apoptosis after superantigen induction and proteins that regulate lymphocyte homeostasis); assays for B cell function and assays for protein that influence early steps of T-cell commitment and development. The above-described assays are
30 described in one or more of the following references:
Current Protocols in Immunology, (John Wiley and Sons, Toronto, 1997); Takai et al., *J. Immunol.* 137:3494-3500 (1986); Bertagnolli et al. *J. Immunol.* 145:1706-1712 (1990); Bertagnolli et al., *Cell. Immunol.* 133:327-341
35 (1991); Bertagnolli et al., *J. Immunol.* 149:3778-3783 (1992); Bowman et al., *J. Immunol.* 152:1756-1761 (1994);

de Vries et al., *J. Exp. Med.* 173:1205-1211 (1991); Moreau et al., *Nature* 336:690-692 (1988); Greenberger et al., *Proc. Natl. Acad. Sci. U.S.A.* 80:2931-2938 (1983); Weinberger et al., *Proc. Natl. Acad. Sci. USA*, 77:6091-5 6095 (1980); Weinberger et al., *Eur. J. Immunol.* 11:405-411 (1981); Takai et al., *J. Immunol.* 140:508-512 (1988); Maliszewski, *J. Immunol.* 144: 3028-3033 (1990); Herrmann et al., *Proc. Natl Acad. Sci USA* 78:24882492 (1981); Herrmann et al., *J. Immunol.* 128:1968-1974 (1982); Handa 10 et al. *J. Immunol.* 135:1564-1572 (1985); Bowman et al., *J. Virology* 61:1992-1998; Brown et al., *J. Immunol.* 153:3079-3092 (1994); Maliszewski, *J. Immunol.* 144:3028-3033 (1990); Guery et al. *J. Immunol.* 134:536-544 (1995); Inaba et al., *J. Exp. Med.* 173:549-559 (1991); Macatonia 15 et al., *J. Immunol.* 154:5071-5079 (1995); Porgador et al., *J. Exp. Med.* 182:255-260 (1995); Nair et al. *J. Virol.* 67:4062-4069 (1993); Huang et al., *Science* 264:961-965 (1994); Macatonia et al., *J. Exp. Med.* 169:1255-1264 (1989); Bhardwaj et al., *J. Clin. Invest.* 94:797-807 20 (1994); Inaba et al., *J. Exp. Med.* 172:631-640 (1990); Darzynkiewicz et al., *Cytometry* 13:795-808 (1992); Gorczyca et al., *Leukemia* 7:659-670 (1993); Gorczyca et al., *Can. Res.* 53:1945-1951 (1993); Itoh et al., *Cell* 66:233-243 (1991); Zacharchuk, *J. Immunol.* 145:4037-4045 25 (1990); Zamai et al. *Cytometry* 14:891-897 (1993); Gorczyca et al., *Inter. J. Oncol.* 1:639-648 (1992); Antica et al., *Blood* 84:111-117 (1994); Fine et al., *Cell. Immunol.* 155:111-122 (1994); Galy et al., *Blood* 85:2770-2778 (1995); and Toki et al., *Proc. Natl. Acad. Sci. USA* 30 88:7548-7551 (1991).

Immune Stimulating/Suppressing Activity

A protein of the present invention may also exhibit immune stimulating or immune suppressing activity including, without limitation, the activities for which assays are described herein. A protein may be useful in the treatment of various immune deficiencies and disorders [including severe combined immunodeficiency (SCID)], e.g., in regulating (up or down) growth and proliferation of T or B lymphocytes., as well as effecting the cytolytic activity of natural killer (NK) cells and other cell populations. These immune deficiencies may be genetic or by caused by viral as well as bacterial or fungal infections or may result from autoimmune disorders. The protein of the present invention by may possibly be used to treat such diseases or to boost the immune system.

Hematopoiesis

The protein of the present invention may be
5 useful in promoting hematopoiesis, including causing
proliferation of red blood cells, megakaryocytes, and
myeloid cells such as monocytes/macrophages. Assays for
relating to stem cell growth or differentiation include:
Freshney, M.G., in *Culture of Hematopoietic Cells*,
10 Frshney, R.I. et al., Eds. (Wiley-Liss, Inc., New York,
N.Y., 1994); Johansson et al. *Cell. Bio.* 15:141-151
(1995); Keller et al., *Mol. & Cell. Bio.* 13:473-486
(1993); McClanahan et al., *Blood* 81:2903-2915 (1993);
Hirayama et al., *Proc. Natl. Acad. Sci. USA* 89:5907-5911
15 (1992); and Neben et al., *Exp. Hematol.* 22:353-359 (1994).

Tissue Regeneration or Repair

The protein of the present invention may be used
20 to repair or regenerate any number of different tissues
including bone, ligaments, tendons, neurons and skin.
Assays for tissue regeneration include those described in
International Patent Publication No. WO95/16035 (bone,
cartilage, tendon); WO95/05846 (neuron); and WO91/07491
25 (skin, endothelium).

Activin/Inhibin Activity

A protein of the present invention may also
30 exhibit activin or inhibin related activities. Inhibin is
a glycoprotein that circulates in plasma and inhibits
gonadotropin-releasing hormone (GnRH)-stimulated follicle
stimulating hormone (FSH) secretion by the pituitary
gland. Activin has the opposite action and stimulates FSH
35 secretion. Thus, the protein of the present invention may
be useful as a contraceptive or as a based upon the

ability of inhibins to decrease fertility in female mammals and decrease spermatogenesis in male mammals. Assays for activin/inhibin activity are described in the following: Vale et al., *Endocrinology* 91:562-572 (1972);
5 Ling et al., *Nature* 321: 779-782 (1986); Vale et al., *Nature* 321:776-779 (1986); Mason et al., *Nature* 318:659-663 (1985); Forage et al., *Proc. Natl. Acad. Sci. USA* 83:3091-3095 (1986).

10 The invention is further illustrated by the following non-limiting examples.

Example 1

15 Discovery of Zchm1 and Construction of Expression Plasmid

Zchm1 cDNA was discovered in a mesentery tumor, sigmoid, mets mixed-mullerian tumor cDNA library. The library was constructed using 1 microgram of polyA RNA
20 isolated from sigmoid mesentery tumor tissue removed from a 61-year-old female during a total abdominal hysterectomy and bilateral salpingo-oophorectomy with regional lymph node excision. Pathology indicated a metastatic grade 4 malignant mixed mullerian tumor present in the sigmoid mesentery at two sites. This tumor was associated with a grade 4 malignant mixed-mullerian tumor, heterologous type, of the uterus, forming a firm, infiltrating mass throughout the myometrium and involving the serosal surface. The heterologous elements of the tumor consisted
25 of rhabdomyoblasts and immature cartilage. The tumor also involved the lower uterine segment and extended into the cervical wall. Extensive lymphatic and vascular permeation was identified in the myometrium and cervical wall. One (of 7) right common iliac and one (of 7) right external
30 iliac lymph nodes were identified with metastatic grade 4 malignant mixed mullerian tumor, with the metastases
35

comprised mainly of adenocarcinoma. There were also positive estrogen and progesterone receptors. cDNA synthesis was initiated using a NotI-oligo(dT) primer. Double-stranded cDNA was blunted, ligated to EcoRI adaptors, digested with NotI, size-selected, and cloned into the NotI and EcoRI sites a plasmid. Expressed sequence tags (EST) from the cDNA library were scanned to discover sequences having homology to the *chondromodulin* gene. The EST of SEQ ID NO:15 was discovered and the clone obtained and sequenced resulting in the *Zchm1* gene of SEQ ID NO:1. The open reading frame of *Zchm-1* was subcloned into vector *pZP9CEE* for expression in mammalian cells. The *pZP9CEE* was the *pZP9* (ATCC 98668) into which DNA encoding a glu-glu epitope tag was inserted. See Grussenmeyer, T. et al., *Proc Natl Acad Sci.* 82:7952 (1985). To facilitate cloning into the vector, a polymerase chain reaction was used to create a *Sal I* and a *Bam HI* sites upstream from the *Zchm-1* initiation codon and downstream from the translation termination codon, respectively. The polymerase chain reaction was carried out in a reaction containing 10 µl of native *Pfu* DNA polymerase buffer, 1 µl of a deoxynucleotide triphosphate solution containing 10 mM each of dATP, dGTP, dTTP and dCTP (Pharmacia LKB Biotechnology Inc., Piscataway, NJ), 5 µl of 7 pmole/µl primer ZC18149 (SEQ ID NO:7), 5 µl of 7 pmole/µl primer ZC18150 (SEQ ID NO: 8), 74 µl of water, 3 µl of 10 ng/µl *Xho I* digested *pSLZchm1-3* template, a plasmid which contained the *Zchm-1* cDNA, and 2 µl of 2.5 U/µl native *Pfu* DNA polymerase (Stratagene Cloning Systems, La Jolla, CA). The polymerase chain reaction was run for 13 cycles (20 seconds at 95° C and 1.5 minutes at 72° C) followed by a 5 minute incubation at 72° C. The amplified products were serially extracted with

phenol/chloroform, chloroform and precipitated with ethanol in the presence of PELLET PAINT[®] carrier (Invitrogen, Carlsbad, CA) and 0.3 M sodium acetate. The pellet was re-suspended in 10 µl water to which was added 5 4 µl of 2X TANGO[®] buffer (MBI Fermentas, Inc.) and 1 µl of 10 U/µl *Sal* I (MBI Fermentas). Digestion was carried out at 37° C for 30 minutes. The reaction was terminated by incubation at 65° C for 15 minutes followed by ethanol precipitation in the presence of 0.3 M sodium acetate. The 10 resulting pellet was resuspended in 10 µl water to which was added 4 µl of 2X TANGO[®] buffer and 1 µl of 10 U/µl *Bam* HI (MBI Fermentas, Inc.). Digestion was carried out at 37° C for 30 minutes. The reaction was terminated by extraction with phenol and chloroform followed by ethanol 15 precipitation in the presence of 0.3 M sodium acetate.

The isolated cDNA inserts described above were ligated into *Xho* I and *Bam* HI digested and dephosphorylated *pZP9CEE* vector. The ligated DNA was 20 transfected into MAXIMUM EFFICIENCY *DH10B*[®] competent cells (Life Technologies, Gaithersburg, MD). The resultant plasmid *pSLZchm1-8* encodes full-length native *Zchm-1* polypeptide.

25 To facilitate detection and purification of the recombinant protein, a Glu tag was added to the C-terminal of *Zchm-1*. The native *Zchm-1* termination codon was removed by sited directed mutagenesis allowing the production of an inframe fusion of the *Zchm-1* C-terminus to a Glu 30 affinity tag encoded by *pZPCEE* vector sequences. A cDNA fragment encoding the mutagenized *Zchm-1* coding sequence was obtained by polymerase chain reaction from 30 ng of *Xho* I digested *pSLZchm103* template employing 5' primer SEQ ID NC:7 and 3' mutagenic primer ZC18987 (SEQ ID NO:9). To

facilitate cloning into *pZP9CEE*, primers SEQ ID NO: 7 and SEQ ID NO:9 incorporate a *Sal* I and *Bam* HI restriction site, respectively. The conditions for polymerase chain reaction and cloning into *pZP9CEE* are identical to that 5 described above for the construction of *pSLZChm1-8*. The resulting plasmid, *pSLZChm1CT-1*, encodes full-length Zchm-1 polypeptide with a C-terminal Glu tag.

Example 2

10 Northern Blot Analysis

A 683 bp *EcoRI/Bgl* II fragment purified from *pSLZchm1-3* was labeled with ^{32}P by random priming. The labeled *Zchm-1* probe was hybridized to multiple tissue 15 Northern Blots (Clontech). The blots were washed at 50° C in 0.1X standard sodium citrate (SSC) buffer and exposed to X-ray film for 5 days with intensifying screens. Northern blot analysis shows a 1.4 kb *Zchm-1* transcript present in poly A mRNA samples purified from skeletal 20 muscle and bone marrow.

Example 3

Chromosomal Localization

25 The *Zchm-1* locus is mapped to chromosome 11p15.4. It was mapped to chromosome 11 using the "GeneBridge 4 Radiation Hybrid Panel" (Research Genetics, Inc., Huntsville, AL). The GeneBridge 4 Radiation Hybrid Panel contains PCR amplifiable DNAs from each of 93 30 radiation hybrid clones, plus two control DNAs (the HFL donor and the A23 recipient). A publicly available WWW server (<http://www-genome.wi.mit.edu/cgi-bin/contig/rhmapper.pl>) allows mapping relative to the Whitehead Institute/MIT center for Genome Research's

radiation hybrid map of the human genome (the "WICGR" radiation hybrid map) which was constructed with the GeneBridge 4 Radiation Hybrid Panel.

5 For the mapping of *Zchm-1* with the "GeneBridge 4 RH Panel", 20 µl reactions were set up in a PCR amplifiable 96-well microtiter plate (Stratagene, La Jolla, CA) and used in a "RoboCycler Gradient 96" thermal cycler (Stratagene). Each of the 95 PCR reactions
10 consisted of 2 µl 10X KlenTaq PCR reaction buffer (Clontech Laboratories, Inc., Palo Alto, CA), 1.6 µl dNTPs mix (2.5 mM each, PE Applied Biosystems, Foster City, CA), 1 µl sense primer ZC 18,314 5' CCG CGT CTG TGA ACC TTT 3'
15 (SEQ ID NO:13), 1 µl antisense primer, ZC 18, 315, 5' GGG CCA CCC ACC AGT TAC 3' (SEQ ID NO:14), 2 µl REDILOAD® (Research Genetics, Inc.), 0.4 µl 50X Advantage KlenTaq Polymerase Mix (Clontech Laboratories, Inc.), 25 ng of DNA from an individual hybrid clone or control and water for a total volume of 20 µl. The reactions were overlaid with an
20 equal amount of mineral oil and sealed. The PCR cycler conditions were as follows: an initial 1 cycle 5 minute denaturation at 95° C, 40 cycles of a 1 minute denaturation at 95° C, 1 minute annealing at 66° C and 1.5 minute extension at 72° C, followed by a final 1 cycle extension
25 of 7 minutes at 72°C. The reactions were separated by electrophoresis on a 2% agarose gel (Life Technologies, Inc., Gaithersburg, MD).

The results showed that *Zchm-1* maps 17.08 cR_3000 from the
30 framework marker *D11S922* on the chromosome 11 WICGR radiation hybrid map. Proximal and distal framework markers were *D11S922* and *D11S932*, respectively. The use of surrounding markers positions *Zchm-1* in the *11p15.4* region on the integrated LDB chromosome 11 map (The Genetic

**Location Database, University of Southampton, WWW server:
http://cedar.genetics.soton.ac.uk/public_html/ .**

CLAIMS:

1. An isolated polynucleotide which encodes a polypeptide selected from the group consisting of SEQ ID NOS: 2, 3, 4, 5, 6, 11 and 12.

2. A polypeptide selected from the group consisting of SEQ ID NOS: 2, 3, 4, 5, 6, 11 and 12.

3. An antibody which specifically binds to a polypeptide selected from the group consisting of SEQ ID NOS: 2, 3, 4, 5, 6, 11 and 12.

SEQUENCE LISTING

<110> ZymoGenetics, Inc.

<120> Mammalian Chondromodulin-like Protein

<130> 98-74PC

<150> 09/191.986

<151> 1998-11-13

<160> 22

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 1178

<212> DNA

<213> Homo sapien

<220>

<221> CDS

<222> (58) (1008)

<400> 1

agcagtggtc tctcagtccct ctc aaaggcaaa ggaaaggatgtt ctgtgtgctg agagacc atg
Met
1

gca aag aat cct cca gag aat tgt gaa gac tgt cac att cta aat gca 108
Ala Lys Asn Pro Pro Glu Asn Cys Glu Asp Cys His Ile Leu Asn Ala
5 10 15

gaa gct ttt aaa tcc aag aaa ata tgt aaa tca ctt aag att tgt gga 156
Glu Ala Phe Lys Ser Lys Lys Ile Cys Lys Ser Leu Lys Ile Cys Gly
20 25 30

ctg gtg ttt ggt atc ctg gcc cta act cta att gtc ctg ttt tgg ggg 204
Leu Val Phe Gly Ile Leu Ala Leu Thr Leu Ile Val Leu Phe Trp Gly
35 40 45

252
agc aag cac ttc tgg ccg gag gta ccc aaa aaa gcc tat gac atg gag
Ser Lys His Phe Trp Pro Glu Val Pro Lys Lys Ala Tyr Asp Met Glu
50 55 60 65

cac act ttc tac agc aat gga gag aag aag att tac atg gaa att His Thr Phe Tyr Ser Asn Gly Glu Lys Lys Ile Tyr Met Glu Ile	300
70 75 80	
gat cct gtg acc aga act gaa ata ttc aga agc gga aat ggc act gat Asp Pro Val Thr Arg Thr Glu Ile Phe Arg Ser Gly Asn Gly Thr Asp	348
85 90 95	
gaa aca ttg gaa gtg cac gac ttt aaa aac gga tac act ggc atc tac Glu Thr Leu Glu Val His Asp Phe Lys Asn Gly Tyr Thr Gly Ile Tyr	396
100 105 110	
ttc gtg ggt ctt caa aaa tgt ttt atc aaa act cag att aaa gtg att Phe Val Gly Leu Gln Lys Cys Phe Ile Lys Thr Gln Ile Lys Val Ile	444
115 120 125	
cct gaa ttt tct gaa cca gaa gag gaa ata gat gag aat gaa gaa att Pro Glu Phe Ser Glu Pro Glu Glu Ile Asp Glu Asn Glu Glu Ile	492
130 135 140 145	
acc aca act ttc ttt gaa cag tca gtg att tgg gtc cca gca gaa aag Thr Thr Thr Phe Phe Glu Gln Ser Val Ile Trp Val Pro Ala Glu Lys	540
150 155 160	
cct att gaa aac cga gat ttt ctt aaa aat tcc aaa att ctg gag att Pro Ile Glu Asn Arg Asp Phe Leu Lys Asn Ser Lys Ile Leu Glu Ile	588
165 170 175	
tgt gat aac gtg acc atg tat tgg atc aat ccc act cta ata tca gtt Cys Asp Asn Val Thr Met Tyr Trp Ile Asn Pro Thr Leu Ile Ser Val	636
180 185 190	
tct gag tta caa gac ttt gag gag gga gaa gat ctt cac ttt cct Ser Glu Leu Gln Asp Phe Glu Glu Glu Gly Asp Leu His Phe Pro	684
195 200 205	
gcc aac gaa aaa aaa ggg att gaa caa aat gaa cag tgg gtg gtc cct Ala Asn Glu Lys Lys Gly Ile Glu Gln Asn Glu Gln Trp Val Val Pro	732
210 215 220 225	
caa gtg aaa gta gag aag acc cgt cac gcc aga caa gca agt gag gaa Gln Val Lys Val Glu Lys Thr Arg His Ala Arg Gln Ala Ser Glu Glu	780
230 235 240	

gaa ctt cca ata aat gac tat act gaa aat gga ata gaa ttt gat ccc 828
 Glu Leu Pro Ile Asn Asp Tyr Thr Glu Asn Gly Ile Glu Phe Asp Pro
 245 250 255

atg ctg gat gag aga ggt tat tgt tgt att tac tgc cgt cga ggc aac 876
Met Leu Asp Glu Arg Gly Tyr Cys Cys Ile Tyr Cys Arg Arg Gly Asn
260 265 270

cgc tat tgc cgc cgc gtc tgt gaa cct tta cta ggc tac tac cca tat 924
Arg Tyr Cys Arg Arg Val Cys Glu Pro Leu Leu Gly Tyr Tyr Pro Tyr
275 280 285

cca tac tgc tac caa gga gga cga gtc atc tgt cgt gtc atc atg cct 972
 Pro Tyr Cys Tyr Gln Gly Gly Arg Val Ile Cys Arg Val Ile Met Pro
 290 295 300 305

tgt aac tgg tgg gtg gcc cgc atg ctg ggg agg gtc taataggagg 1018
Cys Asn Trp Trp Val Ala Arg Met Leu Gly Arg Val
310 315

ttttagctca aatgcttaaa ctgctggcaa catataataa atgcatgcta ttcaatgaat 1078
ttctgcctat gaggcatctg gcccctggta gccagcttc cagaattact tgttaggtaa 1138
tcctctcttc atgttctaat aaacttctac attatcacca 1178

<210> 2
<211> 317
<212> PRT
<213> Homo sapien

<400> 2

Met	Ala	Lys	Asn	Pro	Pro	Glu	Asn	Cys	Glu	Asp	Cys	His	Ile	Leu	Asn
1						5					10				15
Ala	Glu	Ala	Phe	Lys	Ser	Lys	Lys	Ile	Cys	Lys	Ser	Leu	Lys	Ile	Cys
								20			25				30
Gly	Leu	Val	Phe	Gly	Ile	Leu	Ala	Leu	Thr	Leu	Ile	Val	Leu	Phe	Trp
									35		40				45
Gly	Ser	Lys	His	Phe	Trp	Pro	Glu	Val	Pro	Lys	Lys	Ala	Tyr	Asp	Met
									50		55				60
Glu	His	Thr	Phe	Tyr	Ser	Asn	Gly	Glu	Lys	Lys	Ile	Tyr	Met	Glu	
									65		70				80
Ile	Asp	Pro	Val	Thr	Arg	Thr	Glu	Ile	Phe	Arg	Ser	Gly	Asn	Gly	Thr
									85		90				95
Asp	Glu	Thr	Leu	Glu	Val	His	Asp	Phe	Lys	Asn	Gly	Tyr	Thr	Gly	Ile
									100		105				110
Tyr	Phe	Val	Gly	Leu	Gln	Lys	Cys	Phe	Ile	Lys	Thr	Gln	Ile	Lys	Val

	115	120	125
Ile Pro Glu Phe Ser Glu	Pro Glu Glu Glu	Ile Asp Glu Asn Glu Glu	
130	135	140	
Ile Thr Thr Phe Phe Glu Gln Ser Val	Ile Trp Val Pro Ala Glu		
145	150	155	160
Lys Pro Ile Glu Asn Arg Asp Phe Leu Lys	Asn Ser Lys Ile Leu Glu		
165	170	175	
Ile Cys Asp Asn Val Thr Met Tyr Trp Ile Asn Pro Thr Leu Ile Ser			
180	185	190	
Val Ser Glu Leu Gln Asp Phe Glu Glu Gly Glu Asp Leu His Phe			
195	200	205	
Pro Ala Asn Glu Lys Lys Gly Ile Glu Gln Asn Glu Gln Trp Val Val			
210	215	220	
Pro Gln Val Lys Val Glu Lys Thr Arg His Ala Arg Gln Ala Ser Glu			
225	230	235	240
Glu Glu Leu Pro Ile Asn Asp Tyr Thr Glu Asn Gly Ile Glu Phe Asp			
245	250	255	
Pro Met Leu Asp Glu Arg Gly Tyr Cys Cys Ile Tyr Cys Arg Arg Gly			
260	265	270	
Asn Arg Tyr Cys Arg Arg Val Cys Glu Pro Leu Leu Gly Tyr Tyr Pro			
275	280	285	
Tyr Pro Tyr Cys Tyr Gln Gly Gly Arg Val Ile Cys Arg Val Ile Met			
290	295	300	
Pro Cys Asn Trp Trp Val Ala Arg Met Leu Gly Arg Val			
305	310	315	

<210> 3

<211> 15

<212> PRT

<213> Homo sapiens

<400> 3

Leu Val Phe Gly Ile Leu Ala Leu Thr Leu Ile Val Leu Phe Trp			
1	5	10	15

<210> 4

<211> 20

<212> PRT

<213> Homo sapiens

<400> 4

Ile Cys Gly Leu Val Phe Gly Ile Leu Ala Leu Thr Leu Ile Val Leu			
1	5	10	15
Phe Trp Gly Ser			
20			

<210> 5
<211> 103
<212> PRT
<213> Homo sapiens

<400> 5
Gly Ile Glu Gln Asn Glu Gln Trp Val Val Pro Gln Val Lys Val Glu
1 5 10 15
Lys Thr Arg His Ala Arg Gln Ala Ser Glu Glu Leu Pro Ile Asn
20 25 30
Asp Tyr Thr Glu Asn Gly Ile Glu Phe Asp Pro Met Leu Asp Glu Arg
35 40 45
Gly Tyr Cys Cys Ile Tyr Cys Arg Arg Gly Asn Arg Tyr Cys Arg Arg
50 55 60
Val Cys Glu Pro Leu Leu Gly Tyr Tyr Pro Tyr Pro Tyr Cys Tyr Gln
65 70 75 80
Gly Gly Arg Val Ile Cys Arg Val Ile Met Pro Cys Asn Trp Trp Val
85 90 95
Ala Arg Met Leu Gly Arg Val
100

<210> 6
<211> 63
<212> PRT
<213> Homo sapiens

<400> 6
Phe Asp Pro Met Leu Asp Glu Arg Gly Tyr Cys Cys Ile Tyr Cys Arg
1 5 10 15
Arg Gly Asn Arg Tyr Cys Arg Arg Val Cys Glu Pro Leu Leu Gly Tyr
20 25 30
Tyr Pro Tyr Pro Tyr Cys Tyr Gln Gly Gly Arg Val Ile Cys Arg Val
35 40 45
Ile Met Pro Cys Asn Trp Trp Val Ala Arg Met Leu Gly Arg Val
50 55 60

<210> 7
<211> 40
<212> DNA
<213> Homo sapiens

<400> 7
cacgtcgaca ccatggcaa gaatcctcca gagaatttgt

<210> 8

<211> 40

<212> DNA

<213> Homo sapiens

<400> 8

acaggatccc tattagaccc tccccagcat gcgggcccacc 40

<210> 9

<211> 36

<212> DNA

<213> Homo sapiens

<400> 9

acaggatccg accctccca gcatgcggc caccca 36

<210> 10

<211> 4

<212> PRT

<213> Homo sapiens

<400> 10

Arg Glu Arg Arg

1

<210> 11

<211> 110

<212> PRT

<213> Homo sapiens

<400> 11

Glu Gly Glu Asp Leu His Phe Pro Ala Asn Glu Lys Lys Gly Ile Glu

1

5

10

15

Gln Asn Glu Gln Trp Val Val Pro Gln Val Lys Val Glu Lys Thr Arg

20

25

30

His Ala Arg Gln Ala Ser Glu Glu Glu Leu Pro Ile Asn Asp Tyr Thr

35

40

45

Glu Asn Gly Ile Glu Phe Asp Pro Met Leu Asp Glu Arg Gly Tyr Cys

50

55

60

Cys Ile Tyr Cys Arg Arg Gly Asn Arg Tyr Cys Arg Arg Val Cys Glu

65

70

75

80

Pro Leu Leu Gly Tyr Tyr Pro Tyr Pro Cys Tyr Gln Gly Gly Arg

85

90

95

Val Ile Cys Arg Val Ile Met Pro Cys Asn Trp Trp Val Ala

100

105

110

<210> 12
<211> 264
<212> PRT
<213> Homo sapiens

<400> 12
Trp Gly Ser Lys His Phe Trp Pro Glu Val Pro Lys Lys Ala Tyr Asp
1 5 10 15
Met Glu His Thr Phe Tyr Ser Asn Gly Glu Lys Lys Ile Tyr Met
20 25 30
Glu Ile Asp Pro Val Thr Arg Thr Glu Ile Phe Arg Ser Gly Asn Gly
35 40 45
Thr Asp Glu Thr Leu Glu Val His Asp Phe Lys Asn Gly Tyr Thr Gly
50 55 60
Ile Tyr Phe Val Gly Leu Gln Lys Cys Phe Ile Lys Thr Gln Ile Lys
65 70 75 80
Val Ile Pro Glu Phe Ser Glu Pro Glu Glu Ile Asp Glu Asn Glu
85 90 95
Glu Ile Thr Thr Phe Phe Glu Gln Ser Val Ile Trp Val Pro Ala
100 105 110
Glu Lys Pro Ile Glu Asn Arg Asp Phe Leu Lys Asn Ser Lys Ile Leu
115 120 125
Glu Ile Cys Asp Asn Val Thr Met Tyr Trp Ile Asn Pro Thr Leu Ile
130 135 140
Ser Val Ser Glu Leu Gln Asp Phe Glu Glu Glu Gly Glu Asp Leu His
145 150 155 160
Phe Pro Ala Asn Glu Lys Lys Gly Ile Glu Gln Asn Glu Gln Trp Val
165 170 175
Val Pro Gln Val Lys Val Glu Lys Thr Arg His Ala Arg Gln Ala Ser
180 185 190
Glu Glu Glu Leu Pro Ile Asn Asp Tyr Thr Glu Asn Gly Ile Glu Phe
195 200 205
Asp Pro Met Leu Asp Glu Arg Gly Tyr Cys Cys Ile Tyr Cys Arg Arg
210 215 220
Gly Asn Arg Tyr Cys Arg Arg Val Cys Glu Pro Leu Leu Gly Tyr Tyr
225 230 235 240
Pro Tyr Pro Tyr Cys Tyr Gln Gly Gly Arg Val Ile Cys Arg Val Ile
245 250 255
Met Pro Cys Asn Trp Trp Val Ala
260

<210> 13
<211> 18
<212> DNA

<213> Homo sapiens

<400> 13

ccgcgtctgt gaaccttt 18

<210> 14

<211> 18

<212> DNA

<213> Homo sapiens

<400> 14

gggccaccca ccagttac 18

<210> 15

<211> 248

<212> DNA

<213> Homo sapiens

<400> 15

cagcagtngt ctctcagtcc tctcaaagca aggaaagagt actgtgtgct gagagaccat 60
ggcaaagaat cctccagaga atttgtaaga ctgtcacatt ctaaatgcag aagcttttaa 120
atccaagaaa atatgtaaat cacttaagat ttgtggactg gtgttggta tcctggccct 180
aactctaatt gtcctgtttt gggggagcaa gcacttctgg ccggaggta ccaaaaaagc 240
ctatgaca 248

<210> 16

<211> 28

<212> PRT

<213> Homo sapiens

<400> 16

Lys Asn Pro Pro Glu Asn Cys Glu Asp Cys His Ile Leu Asn Ala Glu

1 5 10 15

Ala Phe Lys Ser Lys Lys Ile Cys Lys Ser Leu Lys

20 25

<210> 17

<211> 61

<212> PRT

<213> Homo sapiens

<400> 17

Ser Lys His Phe Trp Pro Glu Val Pro Lys Ala Tyr Asp Met Glu

1 5 10 15

His Thr Phe Tyr Ser Asn Gly Glu Lys Lys Ile Tyr Met Glu Ile

20 25 30
Asp Pro Val Thr Arg Thr Glu Ile Phe Arg Ser Gly Asn Gly Thr Asp
35 40 45
Glu Thr Leu Glu Val His Asp Phe Lys Asn Gly Tyr Thr
50 55 60

<210> 18
<211> 50
<212> PRT
<213> Homo sapiens

<400> 18
Ser Glu Pro Glu Glu Glu Ile Asp Glu Asn Glu Glu Ile Thr Thr Thr
1 5 10 15
Phe Phe Glu Gln Ser Val Ile Trp Val Pro Ala Glu Lys Pro Ile Glu
20 25 30
Asn Arg Asp Phe Leu Lys Asn Ser Lys Ile Leu Glu Ile Cys Asp Asn
35 40 45
Val Thr
50

<210> 19
<211> 87
<212> PRT
<213> Homo sapiens

<400> 19
Glu Leu Gln Asp Phe Glu Glu Glu Gly Glu Asp Leu His Phe Pro Ala
1 5 10 15
Asn Glu Lys Lys Gly Ile Glu Gln Asn Glu Gln Trp Val Val Pro Gln
20 25 30
Val Lys Val Glu Lys Thr Arg His Ala Arg Gln Ala Ser Glu Glu Glu
35 40 45
Leu Pro Ile Asn Asp Tyr Thr Glu Asn Gly Ile Glu Phe Asp Pro Met
50 55 60
Leu Asp Glu Arg Gly Tyr Cys Cys Ile Tyr Cys Arg Arg Gly Asn Arg
65 70 75 80
Tyr Cys Arg Arg Val Cys Glu
85

<210> 20
<211> 54
<212> PRT
<213> Homo sapiens

<400> 20
Lys Val Glu Lys Thr Arg His Ala Arg Gln Ala Ser Glu Glu Glu Leu
1 5 10 15
Pro Ile Asn Asp Tyr Thr Glu Asn Gly Ile Glu Phe Asp Pro Met Leu
20 25 30
Asp Glu Arg Gly Tyr Cys Cys Ile Tyr Cys Arg Arg Gly Asn Arg Tyr
35 40 45
Cys Arg Arg Val Cys Glu
50

<210> 21
<211> 57
<212> PRT
<213> Homo sapiens

<400> 21
Glu Leu Gln Asp Phe Glu Glu Glu Gly Glu Asp Leu His Phe Pro Ala
1 5 10 15
Asn Glu Lys Lys Gly Ile Glu Gln Asn Glu Gln Trp Val Val Pro Gln
20 25 30
Val Lys Val Glu Lys Thr Arg His Ala Arg Gln Ala Ser Glu Glu Glu
35 40 45
Leu Pro Ile Asn Asp Tyr Thr Glu Asn
50 55

<210> 22
<211> 103
<212> PRT
<213> Homo sapiens

<400> 22
Glu Lys Pro Ile Glu Asn Arg Asp Phe Leu Lys Asn Ser Lys Ile Leu
1 5 10 15
Glu Ile Cys Asp Asn Val Thr Met Tyr Trp Ile Asn Pro Thr Leu Ile
20 25 30
Ser Val Ser Glu Leu Gln Asp Phe Glu Glu Glu Gly Glu Asp Leu His
35 40 45
Phe Pro Ala Asn Glu Lys Lys Gly Ile Glu Gln Asn Glu Gln Trp Val
50 55 60
Val Pro Gln Val Lys Val Glu Lys Thr Arg His Ala Arg Gln Ala Ser
65 70 75 80
Glu Glu Glu Leu Pro Ile Asn Asp Tyr Thr Glu Asn Gly Ile Glu Phe
85 90 95
Asp Pro Met Leu Asp Glu Arg
100

INTERNATIONAL SEARCH REPORT

International Application No PCT/US 99/26909

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C12N15/12 C07K14/51 C07K16/22

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C12N C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 99 53051 A (DUCLERT AYMERIC ;GENSET (FR); DUMAS MILNE EDWARDS JEAN BAPTI (FR);) 21 October 1999 (1999-10-21) SEQ.ID. 408 and claims ---	1-3
X	HILLIER ET AL.: "WashU-Merck EST Project." EMBL DATABASE ENTRY HS1154447; ACCESSION NUMBER AA236166,6 March 1997 (1997-03-06), XP002133435 abstract ---	1
A	STRAUSBERG R.: "National Cancer Institute, Cancer Genome Anatomy Project." EMBL DATABASE ENTRY AI123839; ACCESSION NUMBER AI123839, 8 September 1998 (1998-09-08), XP002133436 abstract ---	1-3
	-/-	

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "Z" document member of the same patent family

Date of the actual completion of the international search

17 March 2000

Date of mailing of the international search report

07.04.00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Mandl, B

INTERNATIONAL SEARCH REPORT

International Application No PCT/US 99/26909

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>LIEW C. C. ET AL.: "A catalogue of genes in the cardiovascular system as identified by expressed sequence tags." EMBL DATABASE ENTRY HS1807; ACCESSION NUMBER T12180, 18 December 1994 (1994-12-18), XP002133437 the whole document</p> <p>---</p>	1-3
A	<p>ADAMS M. D. ET AL.: "Initial assessment of human gene diversity and expression patterns based upon 83 million nucleotides of cDNA sequence." EMBL DATABASE ENTRY HSZZ02372; ACCESSION NUMBER AA297231, 18 April 1997 (1997-04-18), XP002133438 abstract</p> <p>-----</p>	1-3

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/26909

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9953051 A	21-10-1999	AU 3050199 A	01-11-1999